



US 20220088231A1

(19) **United States**

(12) **Patent Application Publication**
BURAK et al.

(10) **Pub. No.: US 2022/0088231 A1**

(43) **Pub. Date: Mar. 24, 2022**

(54) **RADIOIMMUNOCONJUGATES AND DNA
DAMAGE AND REPAIR INHIBITOR
COMBINATION THERAPY**

Related U.S. Application Data

(60) Provisional application No. 62/774,847, filed on Dec. 3, 2018.

(71) Applicant: **Fusion Pharmaceuticals Inc.**, Hamilton (CA)

Publication Classification

(51) **Int. Cl.**
A61K 51/10 (2006.01)
A61K 31/5377 (2006.01)
A61P 35/00 (2006.01)
A61K 31/502 (2006.01)
C07K 16/28 (2006.01)

(72) Inventors: **Eric Steven BURAK**, Cambridge (CA);
John Richard FORBES, Burlington (CA); **Meiduo HU**, Maple (CA); **John Fitzmaurice VALLIANT**, Ancaster (CA)

(52) **U.S. Cl.**
CPC *A61K 51/1093* (2013.01); *A61K 31/5377* (2013.01); *C07K 16/2851* (2013.01); *A61K 31/502* (2013.01); *C07K 16/2863* (2013.01); *A61P 35/00* (2018.01)

(21) Appl. No.: **16/619,433**

(22) PCT Filed: **Dec. 3, 2019**

(86) PCT No.: **PCT/IB2019/001292**

§ 371 (c)(1),

(2) Date: **Dec. 4, 2019**

(57) **ABSTRACT**

Combination therapies comprising administering radioimmunoconjugates and DNA damage response inhibitors.

Specification includes a Sequence Listing.




Figure 1




Figure 2B




Figure 2A




Figure 3




Figure 4




Figure 5




Figure 6B




Figure 6A




Figure 7




Figure 8B




Figure 8A




Figure 9




Figure 10




Figure 11




Figure 12




Figure 13B




Figure 13A




Figure 13C

**RADIOIMMUNOCONJUGATES AND DNA
DAMAGE AND REPAIR INHIBITOR
COMBINATION THERAPY**

**CROSS-REFERENCE TO RELATED
APPLICATION**

[0001] The present application is a national stage filing under 35 U.S.C. § 371 of PCT/IB2019/001292, filed Dec. 3, 2019, which claims the benefit of, and priority to, U.S. Provisional Patent Application No. 62/774,847 filed Dec. 3, 2018, the entire contents of each of which are hereby incorporated by reference for all purposes.

SEQUENCE LISTING

[0002] The instant application contains a Sequence Listing which has been submitted electronically in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Nov. 12, 2021, is named FPI-010WOUS_SL.txt and is 14,838 bytes in size.

BACKGROUND

[0003] DNA single stranded breaks and double stranded breaks occur for a variety of reasons, including the presence of mutations in the pathways that include the BRCA, PTEN and ATR proteins. Such DNA breaks are repaired through multiple pathways. PARP inhibition (PARPi) results in an accumulation of single and/or double stranded breaks. Existing PARP inhibitors act through both inhibitors of PARP enzyme inhibition activity and through the trapping of PARP proteins inside of chromatin (“DNA-trapping”). Tumor cells with BRCA and/or PTEN mutations are sensitive to PARPi’s, while ATR inhibition (ATRi) results in a failure to repair double stranded breaks—and therefore results in the accumulation of double stranded breaks. An increase in single or double stranded DNA breaks results in increased cell death.

[0004] DNA Damage Repair inhibitors (DDRi) have been explored as cancer therapeutics. However, inhibiting the repair of DNA strand breaks has been observed to enhance normal tissue toxicity, and many DDRi have exhibited only modest efficacy in vivo. There remains a need for improved treatments of cancer. In particular, there is a need for increases in efficacy, which do not enhance toxicity in the patient.

SUMMARY

[0005] The present disclosure encompasses the insight that combining inhibition of DNA damage repair mechanisms with a therapy that targets DNA breaks to cancer cells may provide a less toxic therapy with improved efficacy. Radioactive decay can cause direct physical damage (such

as single or double-stranded DNA breaks) or indirect damage (such as by-stander or crossfire effects) to the biomolecules that constitute a cell. The present disclosure combines radioimmunoconjugates targeted to cancer cells with DNA damage repair inhibition to treat or ameliorate cancer.

[0006] In one aspect, provided are methods for treating or ameliorating cancer, said methods comprising: (i) administering to a mammal a radioimmunoconjugate, wherein the mammal has received or is receiving a DNA damage response inhibitor (DDRi); (ii) administering to a mammal a DDRi, wherein the mammal has received or is receiving a radioimmunoconjugate; or (iii) administering to the mammal a DDRi at the same time as administering the mammal a radioimmunoconjugate.

[0007] In some embodiments, said method comprises administering to a mammal a DDRi, wherein the mammal has received or is receiving a radioimmunoconjugate.

[0008] In some embodiments, the DDRi is administered in a lower effective dose. In some embodiments, the radioimmunoconjugate is administered in a lower effective dose. In some embodiments, both the DDRi and the radioimmunoconjugate are administered in lower effective doses.

[0009] In some embodiments, the radioimmunoconjugate comprises (i) a targeting moiety, (ii) a linker, and (iii) a chelating moiety or a metal complex of a chelating moiety.

[0010] In some embodiments, the targeting moiety is capable of binding to a tumor-associated antigen.

[0011] In some embodiments, the tumor-associated antigen is a tumor-specific antigen.


[0012] In some embodiments, the targeting moiety is an antibody or an antigen-binding fragment thereof.

[0013] In some embodiments, the antibody or antigen-binding fragment thereof is an IGF1-R antibody or an antigen-binding fragment thereof.

[0014] In some embodiments, the antibody or antigen-binding fragment thereof is an endosialin (TEM-1) antibody or an antigen-binding fragment thereof.

[0015] In some embodiments, the radioimmunoconjugate comprises a metal complex of a chelating moiety. In some embodiments, the metal complex comprises a radionuclide. In some embodiments, the radionuclide is an alpha emitter, e.g., an alpha emitter selected from the group consisting of Astatine-211 (^{211}At), Bismuth-212 (^{212}Bi), Bismuth-213 (^{213}Bi), Actinium-225 (^{225}Ac), Radium-223 (^{223}Ra), Lead-212 (^{212}Pb), Thorium-227 (^{227}Th), and Terbium-149 (^{149}Tb). In some embodiments, the radionuclide is ^{225}Ac .

[0016] In some embodiments, the radioimmunoconjugate comprises the following structure:



[0017] wherein B is the targeting moiety.

[0018] In some embodiments, the DDRi is a PARP inhibitor. In some embodiments, the PARP inhibitor is a small molecule PARP inhibitor, e.g., a PARP inhibitor selected from the group consisting of niparib, niraparib, olaparib, talazoparib, pamiparib, rucaparib (camsylate), and veliparib, or an analog thereof. In some embodiments, the small molecule PARP inhibitor is olaparib or an analog thereof.

[0019] In some embodiments, the DDRi is an ATR inhibitor. In some embodiments, the ATR inhibitor is a small molecule ATR inhibitor, e.g., an ATR inhibitor is selected from the group consisting of AZ20, AZD0156, AZD1390, AZD6738, BAY-1895344, EPT-46464, M3541, M4344, M6620 (formerly known as VE-922 or VX-970), NU6027, VE-821, or an analog thereof. In some embodiments, the ATR inhibitor is BAY-1895344 or an analog thereof.

[0020] In some embodiments, the DDRi is a WEE1 inhibitor, a Chk1 inhibitor, or a Chk2 inhibitor.

[0021] In some embodiments, the DDRi is a DNA-protein kinase (DNA-PK) inhibitor.

[0022] In some embodiments, the mammal is a human.

[0023] In some embodiments, the mammal is diagnosed with cancer.

[0024] In some embodiments, the cancer is selected from the group comprising: breast cancer, non-small cell lung cancer, small cell lung cancer, pancreatic cancer, head and neck cancer, prostate cancer, colorectal cancer, sarcoma, adrenocortical carcinoma, neuroendocrine cancer, Ewing's Sarcoma, multiple myeloma, or acute myeloid leukemia.

[0025] In some embodiments, the mammal has at least one solid tumor.

[0026] In some embodiments, said administering results in a therapeutic effect. In some embodiments, said therapeutic effect comprises a decrease in tumor volume, a stable tumor volume, or a reduced rate of increase in tumor volume. In some embodiments, said therapeutic effect comprises a decreased incidence of recurrence or metastasis.

Definitions

Chemical Terms

[0027] The term “acyl,” as used herein, represents a hydrogen or an alkyl group (e.g., a haloalkyl group), as defined herein, that is attached to the parent molecular group through a carbonyl group, as defined herein, and is exem-

plified by formyl (i.e., a carboxyaldehyde group), acetyl, trifluoroacetyl, propionyl, butanoyl and the like. Exemplary

unsubstituted acyl groups include from 1 to 7, from 1 to 11, or from 1 to 21 carbons. In some embodiments, the alkyl group is further substituted with 1, 2, 3, or 4 substituents as described herein.

[0028] The term “alkyl,” as used herein, is inclusive of both straight chain and branched chain saturated groups from 1 to 20 carbons (e.g., from 1 to 10 or from 1 to 6), unless otherwise specified. Alkyl groups are exemplified by methyl, ethyl, n- and iso-propyl, n-, sec-, iso- and tert-butyl, neopentyl, and the like, and may be optionally substituted with one, two, three, or, in the case of alkyl groups of two carbons or more, four substituents independently selected from the group consisting of: (1) C₁₋₆ alkoxy; (2) C₁₋₆ alkylsulfinyl; (3) amino, as defined herein (e.g., unsubstituted amino (i.e., —NH₂) or a substituted amino (i.e., —N(R^{N1})₂, where R^{N1} is as defined for amino); (4) C₆₋₁₀ aryl-C₁₋₆ alkoxy; (5) azido; (6) halo; (7) (C₂₋₉ heterocyclyl) oxy; (8) hydroxy, optionally substituted with an O-protecting group; (9) nitro; (10) oxo (e.g., carboxyaldehyde or acyl); (11) C₁₋₇ spirocyclyl; (12) thioalkoxy; (13) thiol; (14) —CO₂R^{A'}, optionally substituted with an O-protecting group and where R^{A'} is selected from the group consisting of (a) C₁₋₂₀ alkyl (e.g., C₁₋₆ alkyl), (b) C₂₋₂₀ alkenyl (e.g., C₂₋₆ alkenyl), (c) C₆₋₁₀ aryl, (d) hydrogen, (e) C₁₋₆ alk-C₆₋₁₀ aryl, (f) amino-C₁₋₂₀ alkyl, (g) polyethylene glycol of —(CH₂)_{s2}(OCH₂CH₂)_{s1}(CH₂)_{s3}OR^I, wherein s1 is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and R^I is H or C₁₋₂₀ alkyl, and (h) amino-polyethylene glycol of —NR^{N1}(CH₂)_{s2}(CH₂CH₂O)_{s1}(CH₂)_{s3}NR^{N17} wherein s1 is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and each R^{N1} is, independently, hydrogen or optionally substituted C₁₋₆ alkyl; (15) —C(O)NR^{B'}R^{C'}, where each of R^{B'} and R^{C'} is, independently, selected from the group consisting of (a) hydrogen, (b) C₁₋₆ alkyl, (c) C₆₋₁₀ aryl, and (d) C₁₋₆ alk-C₆₋₁₀ aryl; (16) —SO₂R^{D'}, where R^{D'} is selected from the group consisting of (a) C₁₋₆ alkyl, (b) C₆₋₁₀ aryl, (c) C₁₋₆ alk-C₆₋₁₀ aryl, and (d) hydroxy; (17) —SO₂NR^{E'}R^{F'}, where each of R^{E'} and R^{F'} is, independently, selected from the group consisting of (a) hydrogen, (b) C₁₋₆ alkyl, (c) C₆₋₁₀ aryl and (d) C₁₋₆ alk-C₆₋₁₀ aryl; (18) —C(O)R^{G'} where R^{G'} is selected from the group consisting of (a) C₁₋₂₀ alkyl (e.g., C₁₋₆ alkyl), (b) C₂₋₂₀ alkenyl (e.g., C₂₋₆ alkenyl), (c) C₆₋₁₀ aryl, (d) hydrogen, (e) C₁₋₆ alk-C₆₋₁₀ aryl,

(f) amino- C_{1-20} alkyl, (g) polyethylene glycol of $-(CH_2)_{s2}(OCH_2CH_2)_{s1}(CH_2)_{s3}OR'$, wherein $s1$ is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of $s2$ and $s3$, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and R' is H or C_{1-20} alkyl, and (h) amino-polyethylene glycol of $-NR^{N1}(CH_2)_{s2}(CH_2CH_2O)_{s1}(CH_2)_{s3}NR^{N1}$, wherein $s1$ is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of $s2$ and $s3$, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and each R^{N1} is, independently, hydrogen or optionally substituted C_{1-6} alkyl; (19) $-NR^{H'}C(O)R^{H'}$, wherein $R^{H'}$ is selected from the group consisting of (a1) hydrogen and (b1) C_{1-6} alkyl, and $R^{H'}$ is selected from the group consisting of (a2) C_{1-20} alkyl (e.g., C_{1-6} alkyl), (b2) C_{2-20} alkenyl (e.g., C_{2-6} alkenyl), (c2) C_{6-10} aryl, (d2) hydrogen, (e2) C_{1-6} alk- C_{6-10} aryl, (f2) amino- C_{1-20} alkyl, (g2) polyethylene glycol of $-(CH_2)_{s2}(OCH_2CH_2)_{s1}(CH_2)_{s3}OR'$, wherein $s1$ is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of $s2$ and $s3$, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and R' is H or C_{1-20} alkyl, and (h2) amino-polyethylene glycol of $-NR^{N1}(CH_2)_{s2}(CH_2CH_2O)_{s1}(CH_2)_{s3}NR^{N1}$, wherein $s1$ is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of $s2$ and $s3$, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and each R^{N1} is, independently, hydrogen or optionally substituted C_{1-6} alkyl; (20) $-NR^{K'}C(O)OR^{K'}$, wherein $R^{K'}$ is selected from the group consisting of (a1) hydrogen and (b1) C_{1-6} alkyl, and $R^{K'}$ is selected from the group consisting of (a2) C_{1-20} alkyl (e.g., C_{1-6} alkyl), (b2) C_{2-20} alkenyl (e.g., C_{2-6} alkenyl), (c2) C_{6-10} aryl, (d2) hydrogen, (e2) C_{1-6} alk- C_{6-10} aryl, (f2) amino- C_{1-20} alkyl, (g2) polyethylene glycol of $-(CH_2)_{s2}(OCH_2CH_2)_{s1}(CH_2)_{s3}OR'$, wherein $s1$ is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of $s2$ and $s3$, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and each R^{N1} is, independently, hydrogen or optionally substituted C_{1-6} alkyl; and (21) amidine. In some embodiments, each of these groups can be further substituted as described herein. For example, the alkylene group of a C_1 -alkaryl can be further substituted with an oxo group to afford the respective aryloxy substituent.

[0029] The term “alkylene” and the prefix “alk-,” as used herein, represent a saturated divalent hydrocarbon group derived from a straight or branched chain saturated hydrocarbon by the removal of two hydrogen atoms, and is exemplified by methylene, ethylene, isopropylene, and the like. The term “ C_{x-y} alkylene” and the prefix “ C_{x-y} alk-” represent alkylene groups having between x and y carbons. Exemplary values for x are 1, 2, 3, 4, 5, and 6, and exemplary values for y are 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, or 20 (e.g., C_{1-6} , C_{1-10} , C_{2-20} , C_{2-6} , C_{2-10} , or C_{2-20} alkylene). In some embodiments, the alkylene can be further substituted with 1, 2, 3, or 4 substituent groups as defined herein for an alkyl group.

[0030] The term “alkenyl,” as used herein, represents monovalent straight or branched chain groups of, unless

otherwise specified, from 2 to 20 carbons (e.g., from 2 to 6 or from 2 to 10 carbons) containing one or more carbon-carbon double bonds and is exemplified by ethenyl, 1-propenyl, 2-propenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl, and the like. Alkenyls include both cis and trans isomers. Alkenyl groups may be optionally substituted with 1, 2, 3, or 4 substituent groups that are selected, independently, from amino, aryl, cycloalkyl, or heterocyclyl (e.g., heteroaryl), as defined herein, or any of the exemplary alkyl substituent groups described herein.

[0031] The term “alkynyl,” as used herein, represents monovalent straight or branched chain groups from 2 to 20 carbon atoms (e.g., from 2 to 4, from 2 to 6, or from 2 to 10 carbons) containing a carbon-carbon triple bond and is exemplified by ethynyl, 1-propynyl, and the like. Alkynyl groups may be optionally substituted with 1, 2, 3, or 4 substituent groups that are selected, independently, from aryl, cycloalkyl, or heterocyclyl (e.g., heteroaryl), as defined herein, or any of the exemplary alkyl substituent groups described herein.

[0032] The term “amino,” as used herein, represents $-N(R^{N1})_2$, wherein each R^{N1} is, independently, H, OH, NO_2 , $N(R^{N2})_2$, SO_2OR^{N2} , SO_2R^{N2} , SOR^{N2} , an N-protecting group, alkyl, alkenyl, alkynyl, alkoxy, aryl, alkaryl, cycloalkyl, alkylcycloalkyl, carboxyalkyl (e.g., optionally substituted with an O-protecting group, such as optionally substituted arylalkoxycarbonyl groups or any described herein), sulfoalkyl, acyl (e.g., acetyl, trifluoroacetyl, or others described herein), alkoxycarbonylalkyl (e.g., optionally substituted with an O-protecting group, such as optionally substituted arylalkoxycarbonyl groups or any described herein), heterocyclyl (e.g., heteroaryl), or alkheterocyclyl (e.g., alkheteroaryl), wherein each of these recited R^{N1} groups can be optionally substituted, as defined herein for each group; or two R^{N1} combine to form a heterocyclyl or an N-protecting group, and wherein each R^{N2} is, independently, H, alkyl, or aryl. Amino groups can be unsubstituted amino (i.e., $-NH_2$) or substituted amino (i.e., $-N(R^{N1})_2$) groups. In a preferred embodiment, amino is $-NH_2$ or $-NHR^{N1}$, wherein R^{N1} is, independently, OH, NO_2 , NH_2 , NR^{N2}_2 , SO_2OR^{N2} , SO_2R^{N2} , SOR^{N2} , alkyl, carboxyalkyl, sulfoalkyl, acyl (e.g., acetyl, trifluoroacetyl, or others described herein), alkoxycarbonylalkyl (e.g., t-butoxycarbonylalkyl) or aryl, and each R^{N2} can be H, C_{1-20} alkyl (e.g., C_{1-6} alkyl), or C_{6-10} aryl.

[0033] The term “amino acid,” as described herein, refers to a molecule having a side chain, an amino group, and an acid group (e.g., a carboxy group of $-CO_2H$ or a sulfo group of $-SO_3H$), wherein the amino acid is attached to the parent molecular group by the side chain, amino group, or acid group (e.g., the side chain). In some embodiments, the amino acid is attached to the parent molecular group by a carbonyl group, where the side chain or amino group is attached to the carbonyl group. Exemplary side chains include an optionally substituted alkyl, aryl, heterocyclyl, alkaryl, alkheterocyclyl, aminoalkyl, carbamoylalkyl, and carboxyalkyl. Exemplary amino acids include alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, hydroxyornithine, isoleucine, leucine, lysine, methionine, norvaline, ornithine, phenylalanine, proline, pyrrolysine, selenocysteine, serine, taurine, threonine, tryptophan, tyrosine, and valine. Amino acid groups may be optionally substituted with one, two, three, or, in the case of amino acid groups of two carbons or more, four substituents independently selected from the group

consisting of: (1) C₁₋₆ alkoxy; (2) C₁₋₆ alkylsulfanyl; (3) amino, as defined herein (e.g., unsubstituted amino (i.e., —NH₂) or a substituted amino (i.e., —N(R^{N1})₂, where R^{N1} is as defined for amino); (4) C₆₋₁₀ aryl-C₁₋₆ alkoxy; (5) azido; (6) halo; (7) (C₂₋₉ heterocyclyl)oxy; (8) hydroxy; (9) nitro; (10) oxo (e.g., carboxyaldehyde or acyl); (11) C₁₋₇ spirocyclyl; (12) thioalkoxy; (13) thiol; (14) —CO₂R^{A'} where R^{A'} is selected from the group consisting of (a) C₁₋₂₀ alkyl (e.g., C₁₋₆ alkyl), (b) C₂₋₂₀ alkenyl (e.g., C₂₋₆ alkenyl), (c) C₆₋₁₀ aryl, (d) hydrogen, (e) C₁₋₆ alk-C₆₋₁₀ aryl, (f) amino-C₁₋₂₀ alkyl, (g) polyethylene glycol of —(CH₂)_{s2}(OCH₂CH₂)_{s1}(CH₂)_{s3}OR', wherein s1 is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and R' is H or C₁₋₂₀ alkyl, and (h) amino-polyethylene glycol of —NR^{N1}(CH₂)_{s2}(CH₂CH₂O)_{s1}(CH₂)_{s3}NR^{N1}, wherein s1 is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and each R^{N1} is, independently, hydrogen or optionally substituted C₁₋₆ alkyl; (15) —C(O)NR^{B'}R^{C'}, where each of R^{B'} and R^{C'} is, independently, selected from the group consisting of (a) hydrogen, (b) C₁₋₆ alkyl, (c) C₆₋₁₀ aryl, and (d) C₁₋₆ alk-C₆₋₁₀ aryl; (16) —SO₂R^{D'}, where R^{D'} is selected from the group consisting of (a) C₁₋₆ alkyl, (b) C₆₋₁₀ aryl, (c) C₁₋₆ alk-C₆₋₁₀ aryl, and (d) hydroxy; (17) —SO₂NR^{E'}R^{F'} where each of R^{E'} and R^{F'} is, independently, selected from the group consisting of (a) hydrogen, (b) C₁₋₆ alkyl, (c) C₆₋₁₀ aryl and (d) C₁₋₆ alk-C₆₋₁₀ aryl; (18) —C(O)R^{G'}, where R^{G'} is selected from the group consisting of (a) C₁₋₂₀ alkyl (e.g., C₁₋₆ alkyl), (b) C₂₋₂₀ alkenyl (e.g., C₂₋₆ alkenyl), (c) C₆₋₁₀ aryl, (d) hydrogen, (e) C₁₋₆ alk-C₆₋₁₀ aryl, (f) amino-C₁₋₂₀ alkyl, (g) polyethylene glycol of —(CH₂)_{s2}(OCH₂CH₂)_{s1}(CH₂)_{s3}OR', wherein s1 is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and R' is H or C₁₋₂₀ alkyl, and (h) amino-polyethylene glycol of —NR^{N1}(CH₂)_{s2}(CH₂CH₂O)_{s1}(CH₂)_{s3}NR^{N1}, wherein s1 is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and each R^{N1} is, independently, hydrogen or optionally substituted C₁₋₆ alkyl; (19) —NR^{H'}C(O)R^{I'}, wherein R^{H'} is selected from the group consisting of (a1) hydrogen and (b1) C₁₋₆ alkyl, and R^{I'} is selected from the group consisting of (a2) C₁₋₂₀ alkyl (e.g., C₁₋₆ alkyl), (b2) C₂₋₂₀ alkenyl (e.g., C₂₋₆ alkenyl), (c2) C₆₋₁₀ aryl, (d2) hydrogen, (e2) C₁₋₆ alk-C₆₋₁₀ aryl, (f2) amino-C₁₋₂₀ alkyl, (g2) polyethylene glycol of —(CH₂)_{s2}(OCH₂CH₂)_{s1}(CH₂)_{s3}OR', wherein s1 is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and R' is H or C₁₋₂₀ alkyl, and (h2) amino-polyethylene glycol of —NR^{N1}(CH₂)_{s2}(CH₂CH₂O)_{s1}(CH₂)_{s3}NR^{N1}, wherein s1 is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and each R^{N1} is, independently, hydrogen or optionally substituted C₁₋₆ alkyl; (20) —NR^{J'}C(O)OR^{K'} wherein R^{J'} is selected from the group consisting of (a1) hydrogen and (b1) C₁₋₆ alkyl, and R^{K'} is selected from the group consisting of (a2) C₁₋₂₀ alkyl

(e.g., C₁₋₆ alkyl), (b2) C₂₋₂₀ alkenyl (e.g., C₂₋₆ alkenyl), (c2) C₆₋₁₀ aryl, (d2) hydrogen, (e2) C₁₋₆ alk-C₆₋₁₀ aryl, (f2) amino-C₁₋₂₀ alkyl, (g2) polyethylene glycol of —(CH₂)_{s2}(OCH₂CH₂)_{s1}(CH₂)_{s3}OR', wherein s1 is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and R' is H or C₁₋₂₀ alkyl, and (h2) amino-polyethylene glycol of —NR^{N1}(CH₂)_{s2}(CH₂CH₂O)_{s1}(CH₂)_{s3}NR^{N1}, wherein s1 is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and each R^{N1} is, independently, hydrogen or optionally substituted C₁₋₆ alkyl; and (21) amidine. In some embodiments, each of these groups can be further substituted as described herein.

[0034] The term “aryl,” as used herein, represents a mono-, bicyclic, or multicyclic carbocyclic ring system having one or two aromatic rings and is exemplified by phenyl, naphthyl, 1,2-dihydronaphthyl, 1,2,3,4-tetrahydronaphthyl, anthracenyl, phenanthrenyl, fluorenyl, indanyl, indenyl, and the like, and may be optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of: (1) C₁₋₇ acyl (e.g., carboxyaldehyde); (2) C₁₋₂₀ alkyl (e.g., C₁₋₆ alkyl, C₁₋₆ alkoxy-C₁₋₆ alkyl, C₁₋₆ alkylsulfanyl-C₁₋₆ alkyl, amino-C₁₋₆ alkyl, azido-C₁₋₆ alkyl, (carboxyaldehyde)-C₁₋₆ alkyl, halo-C₁₋₆ alkyl (e.g., perfluoroalkyl), hydroxy-C₁₋₆ alkyl, nitro-C₁₋₆ alkyl, or C₁₋₆ thioalkoxy-C₁₋₆ alkyl); (3) C₁₋₂₀ alkoxy (e.g., C₁₋₆ alkoxy, such as perfluoroalkoxy); (4) C₁₋₆ alkylsulfanyl; (5) C₆₋₁₀ aryl; (6) amino; (7) C₁₋₆ alk-C₆₋₁₀ aryl; (8) azido; (9) C₃₋₈ cycloalkyl; (10) C₁₋₆ alk-C₃₋₈ cycloalkyl; (11) halo; (12) C₁₋₁₂ heterocyclyl (e.g., C₁₋₁₂ heteroaryl); (13) (C₁₋₁₂ heterocyclyl)oxy; (14) hydroxy; (15) nitro; (16) C₁₋₂₀ thioalkoxy (e.g., C₁₋₆ thioalkoxy); (17) —(CH₂)_qCO₂R^{A'}, where q is an integer from zero to four, and R^{A'} is selected from the group consisting of (a) C₁₋₆ alkyl, (b) C₆₋₁₀ aryl, (c) hydrogen, and (d) C₁₋₆ alk-C₆₋₁₀ aryl; (18) —(CH₂)_qCONR^{B'}R^{C'}, where q is an integer from zero to four and where R^{B'} and R^{C'} are independently selected from the group consisting of (a) hydrogen, (b) C₁₋₆ alkyl, (c) C₆₋₁₀ aryl, and (d) C₁₋₆ alk-C₆₋₁₀ aryl; (19) —(CH₂)_qSO₂R^{D'}, where q is an integer from zero to four and where R^{D'} is selected from the group consisting of (a) alkyl, (b) C₆₋₁₀ aryl, and (c) alk-C₆₋₁₀ aryl; (20) —(CH₂)_qSO₂NR^{E'}R^{F'}, where q is an integer from zero to four and where each of R^{E'} and R^{F'} is, independently, selected from the group consisting of (a) hydrogen, (b) C₁₋₆ alkyl, (c) C₁₋₁₀ aryl, and (d) C₁₋₆ alk-C₆₋₁₀ aryl; (21) thiol; (22) C₆₋₁₀ aryloxy; (23) C₃₋₈ cycloalkoxy; (24) C₆₋₁₀ aryl-C₁₋₆ alkoxy; (25) C₁₋₆ alk-C₁₋₁₂ heterocyclyl (e.g., C₁₋₆ alk-C₁₋₁₂ heteroaryl); (26) C₂₋₂₀ alkenyl; and (27) C₂₋₂₀ alkynyl. In some embodiments, each of these groups can be further substituted as described herein. For example, the alkylene group of a C₁-alkaryl or a C₁-alkheterocyclyl can be further substituted with an oxo group to afford the respective aryloyl and (heterocyclyl)oyl substituent group.

[0035] The term “aryllalkyl,” as used herein, represents an aryl group, as defined herein, attached to the parent molecular group through an alkylene group, as defined herein. Exemplary unsubstituted aryllalkyl groups are from 7 to 30 carbons (e.g., from 7 to 16 or from 7 to 20 carbons, such as C₁₋₆ alk-C₆₋₁₀ aryl, C₁₋₁₀ alk-C₆₋₁₀ aryl, or C₁₋₂₀ alk-C₆₋₁₀ aryl). In some embodiments, the alkylene and the aryl each can be further substituted with 1, 2, 3, or 4 substituent groups

as defined herein for the respective groups. Other groups preceded by the prefix “alk-” are defined in the same manner, where “alk” refers to a C₁₋₆ alkylene, unless otherwise noted, and the attached chemical structure is as defined herein.

[0036] The term “carbonyl,” as used herein, represents a C(O) group, which can also be represented as C=O.

[0037] The term “carboxy,” as used herein, means —CO₂H.

[0038] The term “cyano,” as used herein, represents an —CN group.

[0039] The term “cycloalkyl,” as used herein represents a monovalent saturated or unsaturated non-aromatic cyclic hydrocarbon group from three to eight carbons, unless otherwise specified, and is exemplified by cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, bicycle heptyl, and the like. When the cycloalkyl group includes one carbon-carbon double bond or one carbon-carbon triple bond, the cycloalkyl group can be referred to as a “cycloalkenyl” or “cycloalkynyl” group respectively. Exemplary cycloalkenyl and cycloalkynyl groups include cyclopentenyl, cyclohexenyl, cyclohexynyl, and the like. Cycloalkyl groups can be optionally substituted with: (1) C₁₋₇ acyl (e.g., carboxyaldehyde); (2) C₁₋₂₀ alkyl (e.g., C₁₋₆ alkyl, C₁₋₆ alkoxy-C₁₋₆ alkyl, C₁₋₆ alkylsulfanyl-C₁₋₆ alkyl, amino-C₁₋₆ alkyl, azido-C₁₋₆ alkyl, (carboxyaldehyde)-C₁₋₆ alkyl, halo-C₁₋₆ alkyl (e.g., perfluoroalkyl), hydroxy-C₁₋₆ alkyl, nitro-C₁₋₆ alkyl, or C₁₋₆ thioalkoxy-C₁₋₆ alkyl); (3) C₁₋₂₀ alkoxy (e.g., C₁₋₆ alkoxy, such as perfluoroalkoxy); (4) C₁₋₆ alkylsulfanyl; (5) C₆₋₁₀ aryl; (6) amino; (7) C₁₋₆ alk-C₆₋₁₀ aryl; (8) azido; (9) C₃₋₈ cycloalkyl; (10) C₁₋₆ alk-C₃₋₈ cycloalkyl; (11) halo; (12) C₁₋₁₂ heterocyclyl (e.g., C₁₋₁₂ heteroaryl); (13) (C₁₋₁₂ heterocyclyl)oxy; (14) hydroxy; (15) nitro; (16) C₁₋₂₀ thioalkoxy (e.g., C₁₋₆ thioalkoxy); (17) —(CH₂)_qCO₂R^{A'}, where q is an integer from zero to four, and R^{A'} is selected from the group consisting of (a) C₁₋₆ alkyl, (b) C₆₋₁₀ aryl, (c) hydrogen, and (d) C₁₋₆ alk-C₆₋₁₀ aryl; (18) —(CH₂)_qCONR^{B'}R^{C'}, where q is an integer from zero to four and where R^{B'} and R^{C'} are independently selected from the group consisting of (a) hydrogen, (b) C₆₋₁₀ alkyl, (c) C₆₋₁₀ aryl, and (d) C₁₋₆ alk-C₆₋₁₀ aryl; (19) —(CH₂)_qSO₂R^{D'}, where q is an integer from zero to four and where R^{D'} is selected from the group consisting of (a) C₆₋₁₀ alkyl, (b) C₆₋₁₀ aryl, and (c) C₁₋₆ alk-C₆₋₁₀ aryl; (20) —(CH₂)_qSO₂NR^{E'}R^{F'}, where q is an integer from zero to four and where each of R^{E'} and R^{F'} is, independently, selected from the group consisting of (a) hydrogen, (b) C₆₋₁₀ alkyl, (c) C₆₋₁₀ aryl, and (d) C₁₋₆ alk-C₆₋₁₀ aryl; (21) thiol; (22) C₆₋₁₀ aryloxy; (23) C₃₋₈ cycloalkoxy; (24) C₆₋₁₀ aryl-01-6 alkoxy; (25) C₁₋₆ alk-C₁₋₁₂ heterocyclyl (e.g., C₁₋₆ alk-C₁₋₁₂ heteroaryl); (26) oxo; (27) C₂₋₂₀ alkenyl; and (28) C₂₋₂₀ alkynyl. In some embodiments, each of these groups can be further substituted as described herein. For example, the alkylene group of a C₁-alkaryl or a C₁-alkheterocyclyl can be further substituted with an oxo group to afford the respective aryloyl and (heterocyclyl)oyl substituent group.

[0040] The term “diastereomer,” as used herein means stereoisomers that are not mirror images of one another and are non-superimposable on one another.

[0041] The term “enantiomer,” as used herein, means each individual optically active form of a compound, having an optical purity or enantiomeric excess (as determined by methods standard in the art) of at least 80% (i.e., at least 90%

of one enantiomer and at most 10% of the other enantiomer), preferably at least 90% and more preferably at least 98%.

[0042] The term “halogen,” as used herein, represents a halogen selected from bromine, chlorine, iodine, or fluorine.


[0043] The term “heteroalkyl,” as used herein, refers to an alkyl group, as defined herein, in which one or two of the constituent carbon atoms have each been replaced by nitrogen, oxygen, or sulfur. In some embodiments, the heteroalkyl group can be further substituted with 1, 2, 3, or 4 substituent groups as described herein for alkyl groups. The terms “heteroalkenyl” and “heteroalkynyl,” as used herein refer to alkenyl and alkynyl groups, as defined herein, respectively, in which one or two of the constituent carbon atoms have each been replaced by nitrogen, oxygen, or sulfur. In some embodiments, the heteroalkenyl and heteroalkynyl groups can be further substituted with 1, 2, 3, or 4 substituent groups as described herein for alkyl groups.

[0044] The term “heteroaryl,” as used herein, represents that subset of heterocyclyls, as defined herein, which are aromatic: i.e., they contain 4n+2 pi electrons within the mono- or multicyclic ring system. Exemplary unsubstituted heteroaryl groups are of 1 to 12 (e.g., 1 to 11, 1 to 10, 1 to 9, 2 to 12, 2 to 11, 2 to 10, or 2 to 9) carbons. In some embodiment, the heteroaryl is substituted with 1, 2, 3, or 4 substituents groups as defined for a heterocyclyl group.

[0045] The term “heteroarylalkyl” refers to a heteroaryl group, as defined herein, attached to the parent molecular group through an alkylene group, as defined herein. Exemplary unsubstituted heteroarylalkyl groups are from 2 to 32 carbons (e.g., from 2 to 22, from 2 to 18, from 2 to 17, from 2 to 16, from 3 to 15, from 2 to 14, from 2 to 13, or from 2 to 12 carbons, such as C₁₋₆ alk-C₁₋₁₂ heteroaryl, C₁₋₁₀ alk-C₁₋₁₂ heteroaryl, or C₁₋₂₀ alk-C₁₋₁₂ heteroaryl). In some embodiments, the alkylene and the heteroaryl each can be further substituted with 1, 2, 3, or 4 substituent groups as defined herein for the respective group. Heteroarylalkyl groups are a subset of heterocyclylalkyl groups.

[0046] The term “heterocyclyl,” as used herein represents a 5-, 6- or 7-membered ring, unless otherwise specified, containing one, two, three, or four heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur. The 5-membered ring has zero to two double bonds, and the 6- and 7-membered rings have zero to three double bonds. Exemplary unsubstituted heterocyclyl groups are of 1 to 12 (e.g., 1 to 11, 1 to 10, 1 to 9, 2 to 12, 2 to 11, 2 to 10, or 2 to 9) carbons. The term “heterocyclyl” also represents a heterocyclic compound having a bridged multicyclic structure in which one or more carbons and/or heteroatoms bridges two non-adjacent members of a monocyclic ring, e.g., a quinuclidinyl group. The term “heterocyclyl” includes bicyclic, tricyclic, and tetracyclic groups in which any of the above heterocyclic rings is fused to one, two, or three carbocyclic rings, e.g., an aryl ring, a cyclohexane ring, a cyclohexene ring, a cyclopentane ring, a cyclopentene ring, or another monocyclic heterocyclic ring, such as indolyl, quinolyl, isoquinolyl, tetrahydroquinolyl, benzofuryl, benzothienyl and the like. Examples of fused heterocyclyls include tropanes and 1,2,3,5,8,8a-hexahydroindolizine. Heterocyclyls include pyrrolyl, pyrrolinyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, pyrazolidinyl, imidazolyl, imidazolynyl, imidazolidinyl, pyridyl, piperidinyl, homopiperidinyl, pyrazinyl, piperazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiomorpholinyl, thiazolyl, thiazolidinyl,

nyl, isothiazolyl, isothiazolidinyl, indolyl, indazolyl, quinolyl, isoquinolyl, quinoxalyl, dihydroquinoxalyl, quinazolyl, cinnolyl, phthalazinyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, benzothiadiazolyl, furyl, thienyl, thiazolidinyl, isothiazolyl, triazolyl, tetrazolyl, oxadiazolyl (e.g., 1,2,3-oxadiazolyl), purinyl, thiadiazolyl (e.g., 1,2,3-thiadiazolyl), tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, dihydrothienyl, dihydroindolyl, dihydroquinolyl, tetrahydroquinolyl, tetrahydroisoquinolyl, dihydroisoquinolyl, pyranyl, dihydropyranyl, dithiazolyl, benzofuranyl, isobenzofuranyl, benzothieryl, and the like, including dihydro and tetrahydro forms thereof, where one or more double bonds are reduced and replaced with hydrogens. Still other exemplary heterocyclyls include: 2,3,4,5-tetrahydro-2-oxo-oxazolyl; 2,3-dihydro-2-oxo-1H-imidazolyl; 2,3,4,5-tetrahydro-5-oxo-1H-pyrazolyl (e.g., 2,3,4,5-tetrahydro-2-phenyl-5-oxo-1H-pyrazolyl); 2,3,4,5-tetrahydro-2,4-dioxo-1H-imidazolyl (e.g., 2,3,4,5-tetrahydro-2,4-dioxo-5-methyl-5-phenyl-1H-imidazolyl); 2,3-dihydro-2-thioxo-1,3,4-oxadiazolyl (e.g., 2,3-dihydro-2-thioxo-5-phenyl-1,3,4-oxadiazolyl); 4,5-dihydro-5-oxo-1H-triazolyl (e.g., 4,5-dihydro-3-methyl-4-amino-5-oxo-1H-triazolyl); 1,2,3,4-tetrahydro-2,4-dioxopyridinyl (e.g., 1,2,3,4-tetrahydro-2,4-dioxo-3,3-diethylpyridinyl); 2,6-dioxo-piperidinyl (e.g., 2,6-dioxo-3-ethyl-3-phenylpiperidinyl); 1,6-dihydro-6-oxopyridinyl; 1,6-dihydro-4-oxopyrimidinyl (e.g., 2-(methylthio)-1,6-dihydro-4-oxo-5-methylpyrimidin-1-yl); 1,2,3,4-tetrahydro-2,4-dioxopyrimidinyl (e.g., 1,2,3,4-tetrahydro-2,4-dioxo-3-ethylpyrimidinyl); 1,6-dihydro-6-oxopyridazinyl (e.g., 1,6-dihydro-6-oxo-3-ethylpyridazinyl); 1,6-dihydro-6-oxo-1,2,4-triazinyl (e.g., 1,6-dihydro-5-isopropyl-6-oxo-1,2,4-triazinyl); 2,3-dihydro-2-oxo-1H-indolyl (e.g., 3,3-dimethyl-2,3-dihydro-2-oxo-1H-indolyl and 2,3-dihydro-2-oxo-3,3'-spiropyrane-1H-indol-1-yl); 1,3-dihydro-1-oxo-2H-iso-indolyl; 1,3-dihydro-1,3-dioxo-2H-iso-indolyl; 1H-benzopyrazolyl (e.g., 1-(ethoxycarbonyl)-1H-benzopyrazolyl); 2,3-dihydro-2-oxo-1H-benzimidazolyl (e.g., 3-ethyl-2,3-dihydro-2-oxo-1H-benzimidazolyl); 2,3-dihydro-2-oxo-benzoxazolyl (e.g., 5-chloro-2,3-dihydro-2-oxo-benzoxazolyl); 2,3-dihydro-2-oxo-benzoxazolyl; 2-oxo-2H-benzopyranyl; 1,4-benzodioxanyl; 1,3-benzodioxanyl; 2,3-dihydro-3-oxo-4H-1,3-benzothiazinyl; 3,4-dihydro-4-oxo-3H-quinazolyl (e.g., 2-methyl-3,4-dihydro-4-oxo-3H-quinazolyl); 1,2,3,4-tetrahydro-2,4-dioxo-3H-quinazolyl (e.g., 1-ethyl-1,2,3,4-tetrahydro-2,4-dioxo-3H-quinazolyl); 1,2,3,6-tetrahydro-2,6-dioxo-7H-purinyl (e.g., 1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxo-7H-purinyl); 1,2,3,6-tetrahydro-2,6-dioxo-1H-purinyl (e.g., 1,2,3,6-tetrahydro-3,7-dimethyl-2,6-dioxo-1H-purinyl); 2-oxobenz[c,d]indolyl; 1,1-dioxo-2H-naphth[1,8-c,d]isothiazolyl; and 1,8-naphthylenedicarboxamido. Additional heterocyclics include 3,3a,4,5,6,6a-hexahydro-pyrrolo[3,4-b]pyrrol-(2H)-yl, and 2,5-diazabicyclo[2.2.1]heptan-2-yl, homopiperazinyl (or diazepanyl), tetrahydropyranyl, dithiazolyl, benzofuranyl, benzothieryl, oxepanyl, thiopanyl, azocanyl, oxecanyl, and thiocanyl. Heterocyclic groups also include groups of the formula



where

[0047] E' is selected from the group consisting of —N— and —CH—; F' is selected from the group consisting of —N=CH—, —NH—CH₂—, —NH—C(O)—, —NH—, —CH=N—, —CH₂—NH—, —C(O)—NH—, —CH=CH—, —CH₂—, —CH₂CH₂—, —CH₂O—, —OCH₂—, —O—, and —S—; and G' is selected from the group consisting of —CH— and —N—. Any of the heterocyclyl groups mentioned herein may be optionally substituted with one, two, three, four or five substituents independently selected from the group consisting of: (1) C₁₋₇ acyl (e.g., carboxyaldehyde); (2) C₁₋₂₀ alkyl (e.g., C₁₋₆ alkyl, C₁₋₆ alkoxy-C₁₋₆ alkyl, C₁₋₆ alkylsulfanyl-C₁₋₆ alkyl, amino-C₁₋₆ alkyl, azido-C₁₋₆ alkyl, (carboxyaldehyde)-C₁₋₆ alkyl, halo-C₁₋₆ alkyl (e.g., perfluoroalkyl), hydroxy-C₁₋₆ alkyl, nitro-C₁₋₆ alkyl, or C₁₋₆ thioalkoxy-C₁₋₆ alkyl); (3) C₁₋₂₀ alkoxy (e.g., C₁₋₆ alkoxy, such as perfluoroalkoxy); (4) C₁₋₆ alkylsulfanyl; (5) C₆₋₁₀ aryl; (6) amino; (7) C₁₋₆ alk-C₆₋₁₀ aryl; (8) azido; (9) C₃₋₈ cycloalkyl; (10) C₁₋₆ alk-C₃₋₈ cycloalkyl; (11) halo; (12) C₁₋₁₂ heterocyclyl (e.g., C₂₋₁₂ heteroaryl); (13) (C₁₋₁₂ heterocyclyl)oxy; (14) hydroxy; (15) nitro; (16) C₁₋₂₀ thioalkoxy (e.g., C₁₋₆ thioalkoxy); (17) —(CH₂)_qCO₂R^d, where q is an integer from zero to four, and R^d is selected from the group consisting of (a) C₁₋₆ alkyl, (b) C₆₋₁₀ aryl, (c) hydrogen, and (d) C₁₋₆ alk-C₆₋₁₀ aryl; (18) —(CH₂)_qCONR^bR^c, where q is an integer from zero to four and where R^b and R^c are independently selected from the group consisting of (a) hydrogen, (b) C₁₋₆ alkyl, (c) C₆₋₁₀ aryl, and (d) C₁₋₆ alk-C₆₋₁₀ aryl; (19) —(CH₂)_qSO₂R^{d'}, where q is an integer from zero to four and where R^{d'} is selected from the group consisting of (a) C₁₋₆ alkyl, (b) C₆₋₁₀ aryl, and (c) C₁₋₆ alk-C₆₋₁₀ aryl; (20) —(CH₂)_qSO₂NR^eR^f, where q is an integer from zero to four and where each of R^e and R^f is, independently, selected from the group consisting of (a) hydrogen, (b) C₁₋₆ alkyl, (c) C₆₋₁₀ aryl, and (d) C₁₋₆ alk-C₆₋₁₀ aryl; (21) thiol; (22) C₆₋₁₀ aryloxy; (23) C₃₋₈ cycloalkoxy; (24) arylalkoxy; (25) C₁₋₆ alk-C₁₋₁₂ heterocyclyl (e.g., C₁₋₆ alk-C₁₋₁₂ heteroaryl); (26) oxo; (27) (C₁₋₁₂ heterocyclyl)imino; (28) C₂₋₂₀ alkenyl; and (29) C₂₋₂₀ alkynyl. In some embodiments, each of these groups can be further substituted as described herein. For example, the alkylene group of a C₁-alkaryl or a C₁-alkheterocyclyl can be further substituted with an oxo group to afford the respective aryloyl and (heterocyclyl)oyl substituent group.

[0048] The term “hydrocarbon,” as used herein, represents a group consisting only of carbon and hydrogen atoms.

[0049] The term “hydroxyl,” as used herein, represents an —OH group. In some embodiments, the hydroxyl group can be substituted with 1, 2, 3, or 4 substituent groups (e.g., 0-protecting groups) as defined herein for an alkyl.

[0050] The term “isomer,” as used herein, means any tautomer, stereoisomer, enantiomer, or diastereomer of any compound. It is recognized that the compounds can have one or more chiral centers and/or double bonds and, therefore, exist as stereoisomers, such as double-bond isomers (i.e., geometric E/Z isomers) or diastereomers (e.g., enantiomers (i.e., (+) or (–)) or cis/trans isomers). Unless otherwise noted, chemical structures depicted herein encompass all of the corresponding stereoisomers, that is, both the stereomerically pure form (e.g., geometrically pure, enantiomerically pure, or diastereomerically pure) and enantiomeric and stereoisomeric mixtures, e.g., racemates. Enantiomeric and stereoisomeric mixtures of compounds can typically be

resolved into their component enantiomers or stereoisomers by well-known methods, such as chiral-phase gas chromatography, chiral-phase high performance liquid chromatography, crystallizing the compound as a chiral salt complex, or crystallizing the compound in a chiral solvent. Enantiomers and stereoisomers can also be obtained from stereomerically or enantiomerically pure intermediates, reagents, and catalysts by well-known asymmetric synthetic methods.

[0051] The term “N-protected amino,” as used herein, refers to an amino group, as defined herein, to which is attached one or two N-protecting groups, as defined herein.

[0052] The term “N-protecting group,” as used herein, represents those groups intended to protect an amino group against undesirable reactions during synthetic procedures. Commonly used N-protecting groups are disclosed in Greene, “Protective Groups in Organic Synthesis,” 3rd Edition (John Wiley & Sons, New York, 1999), which is incorporated herein by reference. N-protecting groups include acyl, aryloyl, or carbamyl groups such as formyl, acetyl, propionyl, pivaloyl, t-butylacetyl, 2-chloroacetyl, 2-bromoacetyl, trifluoroacetyl, trichloroacetyl, phthalyl, o-nitrophenoxyacetyl, α -chlorobutyryl, benzoyl, 4-chlorobenzoyl, 4-bromobenzoyl, 4-nitrobenzoyl, and chiral auxiliaries such as protected or unprotected D, L or D, L-amino acids such as alanine, leucine, phenylalanine, and the like; sulfonyl-containing groups such as benzenesulfonyl, p-toluenesulfonyl, and the like; carbamate forming groups such as benzyloxycarbonyl, p-chlorobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl, p-bromobenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, 3,5-dimethoxybenzyloxycarbonyl, 2,4-dimethoxybenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 2-nitro-4,5-dimethoxybenzyloxycarbonyl, 3,4,5-trimethoxybenzyloxycarbonyl, 1-(p-biphenyl)-1-methylethoxycarbonyl, α,α -dimethyl-3,5-dimethoxybenzyloxycarbonyl, benzhydryloxy carbonyl, t-butylloxycarbonyl, diisopropylmethoxycarbonyl, isopropylloxycarbonyl, ethoxycarbonyl, methoxycarbonyl, allyloxycarbonyl, 2,2,2-trichloroethoxycarbonyl, phenoxycarbonyl, 4-nitrophenoxycarbonyl, fluorenyl-9-methoxycarbonyl, cyclopentylloxycarbonyl, adamantylloxycarbonyl, cyclohexylloxycarbonyl, phenylthiocarbonyl, and the like, alkaryl groups such as benzyl, triphenylmethyl, benzyloxymethyl, and the like and silyl groups, such as trimethylsilyl, and the like. Preferred N-protecting groups are formyl, acetyl, benzoyl, pivaloyl, t-butylacetyl, alanyl, phenylsulfonyl, benzyl, t-butylloxycarbonyl (Boc), and benzyloxycarbonyl (Cbz).

[0053] The term “O-protecting group,” as used herein, represents those groups intended to protect an oxygen containing (e.g., phenol, hydroxyl, or carbonyl) group against undesirable reactions during synthetic procedures. Commonly used O-protecting groups are disclosed in Greene, “Protective Groups in Organic Synthesis,” 3d Edition (John Wiley & Sons, New York, 1999), which is incorporated herein by reference. Exemplary O-protecting groups include acyl, aryloyl, or carbamyl groups, such as formyl, acetyl, propionyl, pivaloyl, t-butylacetyl, 2-chloroacetyl, 2-bromoacetyl, trifluoroacetyl, trichloroacetyl, phthalyl, o-nitrophenoxyacetyl, α -chlorobutyryl, benzoyl, 4-chlorobenzoyl, 4-bromobenzoyl, t-butyltrimethylsilyl, tri-iso-propylsilyloxymethyl, 4,4'-dimethoxytrityl, isobutyryl, phenoxyacetyl, 4-isopropylphenoxyacetyl, dimethylformamidino, and 4-nitrobenzoyl; alkylcarbonyl groups, such as acyl, acetyl, propionyl, pivaloyl, and the like; optionally substi-

tuted arylcarbonyl groups, such as benzoyl; silyl groups, such as trimethylsilyl (TMS), tert-butyltrimethylsilyl (TBDMS), tri-iso-propylsilyloxymethyl (TOM), triisopropylsilyl (TIPS), and the like; ether-forming groups with the hydroxyl, such as methyl, methoxymethyl, tetrahydropyranyl, benzyl, p-methoxybenzyl, trityl, and the like; alkoxy-carbonyls, such as methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, n-isopropoxycarbonyl, n-butylloxycarbonyl, isobutylloxycarbonyl, sec-butylloxycarbonyl, t-butylloxycarbonyl, 2-ethylhexylloxycarbonyl, cyclohexylloxycarbonyl, methylloxycarbonyl, and the like; alkoxy-alkoxy-carbonyl groups, such as methoxymethoxycarbonyl, ethoxymethoxycarbonyl, 2-methoxyethoxycarbonyl, 2-ethoxyethoxycarbonyl, 2-butoxyethoxycarbonyl, 2-methoxyethoxymethoxycarbonyl, allyloxycarbonyl, propargyloxycarbonyl, 2-butenoxycarbonyl, 3-methyl-2-butenoxycarbonyl, and the like; haloalkoxy-carbonyls, such as 2-chloroethoxycarbonyl, 2-chloroethoxy-carbonyl, 2,2,2-trichloroethoxycarbonyl, and the like; optionally substituted arylalkoxy-carbonyl groups, such as benzyloxycarbonyl, p-methylbenzyloxycarbonyl, p-methoxybenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, 2,4-dinitrobenzyloxycarbonyl, 3,5-dimethylbenzyloxycarbonyl, p-chlorobenzyloxycarbonyl, p-bromobenzyloxy-carbonyl, fluorenylmethylloxycarbonyl, and the like; and optionally substituted aryloxycarbonyl groups, such as phenoxycarbonyl, p-nitrophenoxycarbonyl, o-nitrophenoxycarbonyl, 2,4-dinitrophenoxycarbonyl, p-methyl-phenoxycarbonyl, m-methylphenoxycarbonyl, o-bromophenoxycarbonyl, 3,5-dimethylphenoxycarbonyl, p-chlorophenoxycarbonyl, 2-chloro-4-nitrophenoxy-carbonyl, and the like); substituted alkyl, aryl, and alkaryl ethers (e.g., trityl; methylthiomethyl; methoxymethyl; benzyloxymethyl; siloxymethyl; 2,2,2-trichloroethoxymethyl; tetrahydropyranyl; tetrahydrofuran-yl; ethoxyethyl; 1-[2-(trimethylsilyl)ethoxy]ethyl; 2-trimethylsilylethyl; t-butyl ether; p-chlorophenyl, p-methoxyphenyl, p-nitrophenyl, benzyl, p-methoxybenzyl, and nitrobenzyl); silyl ethers (e.g., trimethylsilyl; triethylsilyl; triisopropylsilyl; dimethylisopropylsilyl; t-butyltrimethylsilyl; t-butyl-diphenylsilyl; tribenzylsilyl; triphenylsilyl; and diphenylmethylsilyl); carbonates (e.g., methyl, methoxymethyl, 9-fluorenylmethyl; ethyl; 2,2,2-trichloroethyl; 2-(trimethylsilyl)ethyl; vinyl, allyl, nitrophenyl; benzyl; methoxybenzyl; 3,4-dimethoxybenzyl; and nitrobenzyl); carbonyl-protecting groups (e.g., acetal and ketal groups, such as dimethyl acetal, 1,3-dioxolane, and the like; acylal groups; and dithiane groups, such as 1,3-dithianes, 1,3-dithiolane, and the like); carboxylic acid-protecting groups (e.g., ester groups, such as methyl ester, benzyl ester, t-butyl ester, orthoesters, and the like; and oxazoline groups.

[0054] The term “oxo” as used herein, represents=O.

[0055] The term “polyethylene glycol,” as used herein, represents an alkoxy chain comprised of one or more monomer units, each monomer unit consisting of $-\text{OCH}_2\text{CH}_2-$. Polyethylene glycol (PEG) is also sometimes referred to as polyethylene oxide (PEO) or polyoxyethylene (POE), and these terms may be considered interchangeable for the purpose of this disclosure. For example, a polyethylene glycol may have the structure, $-(\text{CH}_2)_{s_2}(\text{OCH}_2\text{CH}_2)_{s_1}(\text{CH}_2)_{s_3}\text{O}-$, wherein s_1 is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), and each of s_2 and s_3 , independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10). Polyethylene glycol may also be considered to include an

amino-polyethylene glycol of $\text{—NR}^{\text{N1}}(\text{CH}_2)_{\text{s2}}(\text{CH}_2\text{CH}_2\text{O})_{\text{s1}}(\text{CH}_2)_{\text{s3}}\text{NR}^{\text{N1}}$, wherein s1 is an integer from 1 to 10 (e.g., from 1 to 6 or from 1 to 4), each of s2 and s3, independently, is an integer from 0 to 10 (e.g., from 0 to 4, from 0 to 6, from 1 to 4, from 1 to 6, or from 1 to 10), and each R^{N1} is, independently, hydrogen or optionally substituted C_{1-6} alkyl.

[0056] The term “stereoisomer,” as used herein, refers to all possible different isomeric as well as conformational forms which a compound may possess (e.g., a compound of any formula described herein), in particular all possible stereochemically and conformationally isomeric forms, all diastereomers, enantiomers and/or conformers of the basic molecular structure. Some compounds may exist in different tautomeric forms, all of the latter being included within the scope of the present disclosure.

[0057] The term “sulfonyl,” as used herein, represents an $\text{—S(O)}_2\text{—}$ group.

[0058] The term “thiol,” as used herein represents an —SH group.

Other Terms

[0059] As used herein, the term “administered in combination,” “combined administration,” or “co-administered” means that two or more agents are administered to a subject at the same time or within an interval such that there may be an overlap of an effect of each agent on the patient. Thus, two or more agents that are administered in combination need not be administered together. In some embodiments, they are administered within 90 days (e.g., within 80, 70, 60, 50, 40, 30, 20, 10, 5, 4, 3, 2, or 1 day(s)), within 28 days (e.g., with 14, 7, 6, 5, 4, 3, 2, or 1 day(s)), within 24 hours (e.g., 12, 6, 5, 4, 3, 2, or 1 hour(s)), or within about 60, 30, 15, 10, 5, or 1 minute of one another. In some embodiments, the administrations of the agents are spaced sufficiently closely together such that a combinatorial effect is achieved.

[0060] As used herein, “administering” an agent to a subject includes contacting cells of said subject with the agent.

[0061] As used herein, “antibody” refers to a polypeptide whose amino acid sequence including immunoglobulins and fragments thereof which specifically bind to a designated antigen, or fragments thereof. Antibodies may be of any type (e.g., IgA, IgD, IgE, IgG, or IgM) or subtype (e.g., IgA1, IgA2, IgG1, IgG2, IgG3, or IgG4). Those of ordinary skill in the art will appreciate that a characteristic sequence or portion of an antibody may include amino acid sequences found in one or more regions of an antibody (e.g., variable region, hypervariable region, constant region, heavy chain, light chain, and combinations thereof). Moreover, those of ordinary skill in the art will appreciate that a characteristic sequence or portion of an antibody may include one or more polypeptide chains and may include sequence elements found in the same polypeptide chain or in different polypeptide chains.

[0062] As used herein, “antigen-binding fragment” refers to a portion of an antibody that retains the binding characteristics of the parent antibody.

[0063] The terms “bifunctional chelate” or “bifunctional conjugate” as used interchangeably herein, refer to a compound that contains a chelating group or metal complex thereof, a linker group, and a therapeutic moiety, targeting moiety, or cross-linking group.

[0064] The term “cancer” refers to any cancer caused by the proliferation of malignant neoplastic cells, such as

tumors, neoplasms, carcinomas, sarcomas, leukemias, and lymphomas. A “solid tumor cancer” is a cancer comprising an abnormal mass of tissue, e.g., sarcomas, carcinomas, and lymphomas. A “hematological cancer” or “liquid cancer,” as used interchangeably herein, is a cancer present in a body fluid, e.g., lymphomas and leukemias.

[0065] The term “chelate” as used herein, refers to an organic compound or portion thereof that can be bonded to a central metal or radiometal atom at two or more points.

[0066] The term “conjugate,” as used herein, refers to a molecule that contains a chelating group or metal complex thereof, a linker group, and which optionally contains a therapeutic moiety, targeting moiety, or cross-linking group.

[0067] As used herein, the term “compound,” is meant to include all stereoisomers, geometric isomers, and tautomers of the structures depicted.

[0068] The compounds described herein can be asymmetric (e.g., having one or more stereocenters).

[0069] All stereoisomers, such as enantiomers and diastereomers, are intended unless otherwise indicated.

[0070] Compounds of the present disclosure that contain asymmetrically substituted carbon atoms can be isolated in optically active or racemic forms. Methods on how to prepare optically active forms from optically active starting materials are known in the art, such as by resolution of racemic mixtures or by stereoselective synthesis. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present disclosure. Cis and trans geometric isomers of the compounds of the present disclosure are described and may be isolated as a mixture of isomers or as separated isomeric forms.

[0071] Compounds of the present disclosure also include tautomeric forms. Tautomeric forms result from the swapping of a single bond with an adjacent double bond and the concomitant migration of a proton. Tautomeric forms include prototropic tautomers which are isomeric protonation states having the same empirical formula and total charge. Examples prototropic tautomers include ketone—enol pairs, amide—imidic acid pairs, lactam—lactim pairs, amide—imidic acid pairs, enamine—imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, such as, 1H- and 3H-imidazole, 1H-, 2H- and 4H-1,2,4-triazole, 1H- and 2H-isindole, and 1H- and 2H-pyrazole. Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution.

[0072] At various places in the present specification, substituents of compounds of the present disclosure are disclosed in groups or in ranges. It is specifically intended that the present disclosure include each and every individual subcombination of the members of such groups and ranges. For example, the term “ C_{1-6} alkyl” is specifically intended to individually disclose methyl, ethyl, C_3 alkyl, C_4 alkyl, C_5 alkyl, and C_6 alkyl. Herein a phrase of the form “optionally substituted X” (e.g., optionally substituted alkyl) is intended to be equivalent to “X, wherein X is optionally substituted” (e.g., “alkyl, wherein said alkyl is optionally substituted”). It is not intended to mean that the feature “X” (e.g., alkyl) per se is optional.

[0073] The term “cross-linking group” as used herein refers to any reactive group that is able to join two or more molecules by a covalent bond. In some embodiments, the

cross-linking group is an amino-reactive orthiol-reactive cross-linking group. In some embodiments, the amino-reactive orthiol-reactive cross-linking group comprises an activated ester such as a hydroxysuccinimide ester, 2,3,5,6-tetrafluorophenol ester, 4-nitrophenol ester or an imidate, anhydride, thiol, disulfide, maleimide, azide, alkyne, strained alkyne, strained alkene, halogen, sulfonate, haloacetyl, amine, hydrazide, diazirine, phosphine, tetrazine, isothiocyanate. In some embodiments, the cross-linking group may be glycine-glycine-glycine and/or leucine-proline-(any amino acid)-threonine-glycine, which are the recognition sequences for coupling targeting agents with the linker using a sortase-mediated coupling reaction. The person having ordinary skill in the art will understand that the use of cross-linking groups are not limited to the specific constructs disclosed herein, but rather may include other known cross-linking groups.

[0074] As used herein, the terms “decrease,” “decreased,” “increase,” “increased,” or “reduction,” “reduced,” (e.g., in reference to therapeutic outcomes or effects) have meanings relative to a reference level. In some embodiments, the reference level is a level as determined by the use of said method with a control in an experimental animal model or clinical trial. In some embodiments, the reference level is a level in the same subject before or at the beginning of treatment. In some embodiments, the reference level is the average level in a population not being treated by said method of treatment.

[0075] As used herein “detection agent” refers to a molecule or atom which is useful in diagnosing a disease by locating the cells containing the antigen. Various methods of labeling polypeptides with detection agents are known in the art. Examples of detection agents include, but are not limited to, radioisotopes and radionuclides, dyes (such as with the biotin-streptavidin complex), contrast agents, luminescent agents (e.g., FITC, rhodamine, lanthanide phosphors, cyanine, and near IR dyes), and magnetic agents, such as gadolinium chelates.

[0076] The term “DNA damage and repair inhibitor” (DDRi) refers to an agent which prevents the repair of cellular DNA damage caused by endogenous or exogenous chromosomal insults, and which acts through the inhibition of normally occurring DNA repair mechanisms and associated processes necessary for the maintenance of cellular viability.

[0077] The term an “effective amount” of an agent (e.g., any of the foregoing conjugates), as used herein, is that amount sufficient to effect beneficial or desired results, such as clinical results, and, as such, an “effective amount” depends upon the context in which it is being applied.

[0078] The term “immunoconjugate,” as used herein, refers to a conjugate that includes a targeting moiety, such as an antibody, nanobody, affibody, or a consensus sequence from Fibronectin type III domain. In some embodiments, the immunoconjugate comprises an average of at least 0.10 conjugates per targeting moiety (e.g., an average of at least 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 4, 5, or 8 conjugates per targeting moiety).

[0079] The term “lower effective dose,” when used as a term in conjunction with an agent (e.g., a therapeutic agent) refers to a dosage of the agent which is effective therapeutically in the combination therapies of the invention and which is lower than the dose which has been determined to

be effective therapeutically when the agent is used as a monotherapy in reference experiments or by virtue of other therapeutic guidance.

[0080] The term “pharmaceutical composition,” as used herein, represents a composition containing a compound described herein formulated with a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition is manufactured or sold with the approval of a governmental regulatory agency as part of a therapeutic regimen for the treatment of disease in a mammal. Pharmaceutical compositions can be formulated, for example, for oral administration in unit dosage form (e.g., a tablet, capsule, caplet, gelcap, or syrup); for topical administration (e.g., as a cream, gel, lotion, or ointment); for intravenous administration (e.g., as a sterile solution free of particulate emboli and in a solvent system suitable for intravenous use); or in any other formulation described herein.

[0081] A “pharmaceutically acceptable excipient,” as used herein, refers any ingredient other than the compounds described herein (for example, a vehicle capable of suspending or dissolving the active compound) and having the properties of being nontoxic and non-inflammatory in a patient. Excipients may include, for example: antiadherents, antioxidants, binders, coatings, compression aids, disintegrants, dyes (colors), emollients, emulsifiers, fillers (diluent), film formers or coatings, flavors, fragrances, glidants (flow enhancers), lubricants, preservatives, printing inks, radioprotectants, sorbents, suspending or dispersing agents, sweeteners, or waters of hydration. Exemplary excipients include, but are not limited to: ascorbic acid, histidine, phosphate buffer, butylated hydroxytoluene (BHT), calcium carbonate, calcium phosphate (dibasic), calcium stearate, croscarmellose, crosslinked polyvinyl pyrrolidone, citric acid, crospovidone, cysteine, ethylcellulose, gelatin, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose, magnesium stearate, maltitol, mannitol, methionine, methylcellulose, methyl paraben, microcrystalline cellulose, polyethylene glycol, polyvinyl pyrrolidone, povidone, pregelatinized starch, propyl paraben, retinyl palmitate, shellac, silicon dioxide, sodium carboxymethyl cellulose, sodium citrate, sodium starch glycolate, sorbitol, starch (corn), stearic acid, sucrose, talc, titanium dioxide, vitamin A, vitamin E, vitamin C, and xylitol.

[0082] The term “pharmaceutically acceptable salt,” as used herein, represents those salts of the compounds described here that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and animals without undue toxicity, irritation, or allergic response.

[0083] Pharmaceutically acceptable salts are well known in the art. For example, pharmaceutically acceptable salts are described in: Berge et al., *J. Pharmaceutical Sciences* 66:1-19, 1977 and in *Pharmaceutical Salts: Properties, Selection, and Use*, (Eds. P. H. Stahl and C. G. Wermuth), Wiley-VCH, 2008. The salts can be prepared in situ during the final isolation and purification of the compounds described herein or separately by reacting the free base group with a suitable organic acid.

[0084] Compounds may have ionizable groups so as to be capable of preparation as pharmaceutically acceptable salts. These salts may be acid addition salts involving inorganic or organic acids or the salts may, in the case of acidic forms of compounds, be prepared from inorganic or organic bases. Frequently, the compounds are prepared or used as pharma-

aceutically acceptable salts prepared as addition products of pharmaceutically acceptable acids or bases. Suitable pharmaceutically acceptable acids and bases are well-known in the art, such as hydrochloric, sulphuric, hydrobromic, acetic, lactic, citric, or tartaric acids for forming acid addition salts, and potassium hydroxide, sodium hydroxide, ammonium hydroxide, caffeine, various amines for forming basic salts. Methods for preparation of the appropriate salts are well-established in the art.

[0085] Representative acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptonate, hexanoate, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate, undecanoate, valerate salts, among others. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, and magnesium, as well as nontoxic ammonium, quaternary ammonium, and amine cations, including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, and ethylamine.

[0086] The term “polypeptide” as used herein refers to a string of at least two amino acids attached to one another by a peptide bond. In some embodiments, a polypeptide may include at least 3-5 amino acids, each of which is attached to others by way of at least one peptide bond. Those of ordinary skill in the art will appreciate that polypeptides can include one or more “non-natural” amino acids or other entities that nonetheless are capable of integrating into a polypeptide chain. In some embodiments, a polypeptide may be glycosylated, e.g., a polypeptide may contain one or more covalently linked sugar moieties. In some embodiments, a single “polypeptide” (e.g., an antibody polypeptide) may comprise two or more individual polypeptide chains, which may in some cases be linked to one another, for example by one or more disulfide bonds or other means.

[0087] The term “radioconjugate,” as used herein, refers to any conjugate that includes a radioisotope or radionuclide, such as any of the radioisotopes or radionuclides described herein.

[0088] The term “radioimmunoconjugate,” as used herein, refers to any immunoconjugate that includes a radioisotope or radionuclide, such as any of the radioisotopes or radionuclides described herein.

[0089] The term “radioimmunotherapy,” as used herein, refers a method of using a radioimmunoconjugate to produce a therapeutic effect. In some embodiments, radioimmunotherapy may include administration of a radioimmunoconjugate to a subject in need thereof, wherein administration of the radioimmunoconjugate produces a therapeutic effect in the subject. In some embodiments, radioimmunotherapy may include administration of a radioimmunoconjugate to a cell, wherein administration of the radioimmunoconjugate kills the cell. Wherein radioimmu-

notherapy involves the selective killing of a cell, in some embodiments the cell is a cancer cell in a subject having cancer.

[0090] As used herein, the term “radionuclide,” refers to an atom capable of undergoing radioactive decay (e.g., ^3H , ^{14}C , ^{15}N , ^{18}F , ^{35}S , ^{47}Sc , ^{55}C , ^{60}Cu , ^{61}Cu , ^{62}Cu , ^{64}Cu , ^{67}Cu , ^{75}Br , ^{76}Br , ^{77}Br , ^{89}Zr , ^{86}Y , ^{87}Y , ^{90}Y , ^{97}Ru , ^{99}Tc , $^{99\text{m}}\text{Tc}$, ^{105}Rh , ^{109}Pd , ^{111}In , ^{123}I , ^{124}I , ^{125}I , ^{131}I , ^{149}Pm , ^{149}Tb , ^{153}Sm , ^{166}Ho , ^{177}Lu , ^{186}Re , ^{188}Re , ^{198}Au , ^{199}Au , ^{203}Pb , ^{211}At , ^{212}Pb , ^{212}Bi , ^{213}Bi , ^{223}Ra , ^{225}Ac , ^{227}Th , ^{229}Th , ^{67}Ga , ^{68}Ga , ^{82}Rb , $^{117\text{m}}\text{Sn}$, ^{201}Tl). The terms radioactive nuclide, radioisotope, or radioactive isotope may also be used to describe a radionuclide. Radionuclides may be used as detection agents, as described above. In some embodiments, the radionuclide is an alpha-emitting radionuclide.

[0091] By “subject” is meant a human or non-human animal (e.g., a mammal).

[0092] By “substantial identity” or “substantially identical” is meant a polypeptide sequence that has the same polypeptide sequence, respectively, as a reference sequence, or has a specified percentage of amino acid residues, respectively, that are the same at the corresponding location within a reference sequence when the two sequences are optimally aligned. For example, an amino acid sequence that is “substantially identical” to a reference sequence has at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the reference amino acid sequence. For polypeptides, the length of comparison sequences will generally be at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 50, 75, 90, 100, 150, 200, 250, 300, or 350 contiguous amino acids (e.g., a full-length sequence). Sequence identity may be measured using sequence analysis software, e.g., on the default setting (e.g., Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wis. 53705). Such software may match similar sequences by assigning degrees of homology to various substitutions, deletions, and other modifications.

[0093] The term “targeting moiety” as used herein refers to any molecule or any part of a molecule that binds to a given target. In some embodiments, the targeting moiety is a protein or polypeptide such as an antibody or antigen binding fragment thereof, a nanobody, an affibody, or a consensus sequence from a Fibronectin type III domain.

[0094] The term “therapeutic moiety” as used herein refers to any molecule or any part of a molecule that confers a therapeutic benefit. In some embodiments, the therapeutic moiety is a protein or polypeptide, e.g., an antibody, an antigen-binding fragment thereof. In some embodiments, the therapeutic moiety is a small molecule.

[0095] As used herein, and as well understood in the art, “to treat” a condition or “treatment” of the condition (e.g., the conditions described herein such as cancer) is an approach for obtaining beneficial or desired results, such as clinical results. Beneficial or desired results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions; diminishment of extent of disease, disorder, or condition; stabilized (i.e., not worsening) state of disease, disorder, or condition; preventing spread of disease, disorder, or condition; delay or slowing the progress of the disease, disorder, or condition; amelioration or palliation of the disease, disorder, or condition; and remission (whether partial or total), whether detectable or undetectable. In the context of cancer treatment, “ameliorating” may

include, for example, reducing incidence of metastases, reducing tumor volume, reducing tumor vascularization and/or reducing the rate of tumor growth. “Palliating” a disease, disorder, or condition means that the extent and/or undesirable clinical manifestations of the disease, disorder, or condition are lessened and/or time course of the progression is slowed or lengthened, as compared to the extent or time course in the absence of treatment.

[0096] As used herein, the term “tumor-associated antigen” means an antigen that is present on tumor cells at a significantly greater amount than on normal cells.

[0097] As used herein, the term “tumor-specific antigen” refers to an antigen that is endogenously present only on tumor cells.

BRIEF DESCRIPTION OF THE DRAWINGS

[0098] FIG. 1 is a schematic demonstrating the dosing schedule for [²²⁵Ac]-FPI-1434 and BAY-1895344 (an ATR inhibitor) in two xenograft models: Colo-205 and A549. See Example 1.

[0099] FIGS. 2A-2B illustrate the relative tumor volume in Colo-205 (FIG. 2A) and A549 (FIG. 2B) after treatment with BAY-1895344 and [²²⁵Ac]-FPI-1434 alone or in combination. See Example 1.

[0100] FIG. 3 is a schematic demonstrating the dosing schedule for [²²⁵Ac]-FPI-1434 and BAY-1895344 in the Colo-205 (colorectal cancer) xenograft model. See Example 2.

[0101] FIG. 4 illustrates the relative tumor volume in Colo-205 after treatment with BAY-1895344 and [²²⁵Ac]-FPI-1434 alone or in combination. See Example 2.

[0102] FIG. 5 is a schematic demonstrating the dosing schedule for olaparib for treatment in two xenograft models: Colo-205 and A549. See Example 3.

[0103] FIGS. 6A-6B illustrate relative tumor volume in Colo-205 (FIG. 6A) and A549 (FIG. 6B) after treatment with olaparib. See Example 3.

[0104] FIG. 7 is a schematic demonstrating the dosing schedule for [²²⁵Ac]-FPI-1434 and olaparib for treatment in two xenograft models: Colo-205 and A549. See Example 4.

[0105] FIGS. 8A-8B illustrate relative tumor volume in Colo-205 (FIG. 8A) and A549 (FIG. 8B) after treatment with olaparib and [²²⁵Ac]-FPI-1434 alone or in combination. See Example 4.

[0106] FIG. 9 is a schematic demonstrating the dosing schedule for [²²⁵Ac]-FPI-1434 and olaparib for treatment in the Colo-205 xenograft model. See Example 5.

[0107] FIG. 10 illustrates relative tumor volume in Colo-205 after treatment with olaparib and [²²⁵Ac]-FPI-1434 alone or in combination. See Example 5.

[0108] FIG. 11 is a schematic demonstrating the dosing schedule for [²²⁵Ac]-FPI-1434 and olaparib used in the multiple-dose in vivo experiments described in Example 6.

[0109] FIG. 12 shows relative tumor volumes in animals administered lower effective doses of [²²⁵Ac]-FPI-1434 (20 nCi) and olaparib (25 mg/kg) in the experiment described in Example 6.

[0110] FIGS. 13A-13C show relative tumor volumes in animals administered 20 nCi (FIG. 13A), 50 nCi (FIG. 13B), or 100 nCi (FIG. 13C) [²²⁵Ac]-FPI-1434 with olaparib (25 mg/kg or 50 mg/kg).

[0111] It is to be understood that the figures are not necessarily drawn to scale, nor are the objects in the figures

necessarily drawn to scale in relationship to one another. The figures are depictions that are intended to bring clarity and understanding to various embodiments of apparatuses, systems, and methods disclosed herein. Wherever possible, the same reference numbers will be used throughout the drawings to refer to the same or like parts. Moreover, it should be appreciated that the drawings are not intended to limit the scope of the present teachings in any way.

DETAILED DESCRIPTION

[0112] The present disclosure relates to combination therapies for treating or ameliorating cancer, using radioimmunoconjugates and DNA damage and repair inhibitors (DDRIs). In some embodiments, a lower effective dose of the radioimmunoconjugate and/or of the DDRi is used.

[0113] Radiolabelled targeting moieties (also known as radioimmunoconjugates) are designed to target a protein or receptor that is upregulated in a disease state and/or specific to diseased cells (e.g., tumor cells) to deliver a radioactive payload to damage and kill cells of interest. “Radioimmunotherapy” refers to this therapy when the targeting moiety comprises an antibody, typically a monoclonal antibody.

[0114] Radioactive decay of the payload produces an alpha, beta, or gamma particle or Auger electron that can cause direct effects to DNA (such as single or double stranded DNA breaks) or indirect effects such as by-stander or crossfire effects.

[0115] Radioimmunoconjugates typically contain a biological targeting moiety (e.g., an antibody or antigen binding fragment thereof that specifically binds to a molecule expressed on or by a tumor, e.g., IGF-1R or TEM-1/endosialin), a chelating moiety or a metal complex of a chelating moiety (e.g., comprising a radioisotope), and a linker. Conjugates may be formed by appending a bifunctional chelate to the biological targeting molecule so that structural alterations are minimal while maintaining target affinity. A radioimmunoconjugate may be formed by radiolabelling such a conjugate.

[0116] Bifunctional chelates structurally contain a chelate, a linker, and a cross-linking group. When developing new bifunctional chelates, most efforts focus around the chelating portion of the molecule. Several examples of bifunctional chelates have been described with various cyclic and acyclic structures conjugated to a targeted moiety. [Bioconjugate Chem. 2000, 11, 510-519, Bioconjugate Chem. 2012, 23, 1029-1039, Mol Imaging Biol (2011) 13:215-221, Bioconjugate Chem. 2002,13,110-115].

[0117] Radioimmunoconjugates

[0118] Radioimmunoconjugates suitable for use in accordance with the present disclosure generally have the structure of Formula I-a:

A-L-B


Formula I-a

[0119] wherein A is a chelating moiety or metal complex thereof),

[0120] wherein B is a targeting moiety, and

[0121] wherein L is a linker.

[0122] In some embodiments, the radioimmunoconjugate comprises the following structure:



wherein B is the targeting moiety.

[0123] Targeting Moieties

[0124] Targeting moieties include any molecule or any part of a molecule that is capable of binding to a given target. In some embodiments, the targeting moiety comprises a protein or polypeptide. In some embodiments, the targeting moiety is selected from the group consisting of antibodies or antigen binding fragments thereof, nanobodies, affibodies, and consensus sequences from Fibronectin type III domains (e.g., Centyrins or Adnectins). In some embodiments, a moiety is both a targeting and a therapeutic moiety, i.e., the moiety is capable of binding to a given target and also confers a therapeutic benefit.

[0125] Antibodies

[0126] Antibodies typically comprise two identical light polypeptide chains and two identical heavy polypeptide chains linked together by disulfide bonds. The first domain located at the amino terminus of each chain is variable in amino acid sequence, providing the antibody-binding specificities of each individual antibody. These are known as variable heavy (VH) and variable light (VL) regions. The other domains of each chain are relatively invariant in amino acid sequence and are known as constant heavy (CH) and constant light (CL) regions. Light chains typically comprise one variable region (VL) and one constant region (CL). An IgG heavy chain includes a variable region (VH), a first constant region (CH1), a hinge region, a second constant region (CH2), and a third constant region (CH3). In IgE and IgM antibodies, the heavy chain includes an additional constant region (CH4).

[0127] Antibodies described herein can include, for example, monoclonal antibodies, polyclonal antibodies, multispecific antibodies, human antibodies, humanized antibodies, camelid antibodies, chimeric antibodies, single-chain Fvs (scFv), disulfide-linked Fvs (sdFv), and anti-idiotypic (anti-Id) antibodies, and antigen-binding fragments of any of the above. In some embodiments, the antibody or antigen-binding fragment thereof is humanized. In some embodiments, the antibody or antigen-binding fragment thereof is chimeric. Antibodies can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass.

[0128] The term “antigen binding fragment” of an antibody, as used herein, refers to one or more fragments of an antibody that retain the ability to specifically bind to an

antigen. Examples of binding fragments encompassed within the term “antigen binding fragment” of an antibody

include a Fab fragment, a F(ab')₂ fragment, a Fd fragment, a Fv fragment, a scFv fragment, a dAb fragment (Ward et al., (1989) Nature 341:544-546), and an isolated complementarity determining region (CDR). In some embodiments, an “antigen binding fragment” comprises a heavy chain variable region and a light chain variable region. These antibody fragments can be obtained using conventional techniques known to those with skill in the art, and the fragments can be screened for utility in the same manner as are intact antibodies.

[0129] Antibodies or fragments described herein can be produced by any method known in the art for the synthesis of antibodies (see, e.g., Harlow et al., *Antibodies: A Laboratory Manual*, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988); Brinkman et al., 1995, *J. Immunol. Methods* 182:41-50; WO 92/22324; WO 98/46645). Chimeric antibodies can be produced using the methods described in, e.g., Morrison, 1985, *Science* 229:1202, and humanized antibodies by methods described in, e.g., U.S. Pat. No. 6,180,370.

[0130] Additional antibodies described herein are bispecific antibodies and multivalent antibodies, as described in, e.g., Segal et al., *J. Immunol. Methods* 248:1-6 (2001); and Tutt et al., *J. Immunol.* 147: 60 (1991).

[0131] Insulin-Like Growth Factor 1 (IGF-1R) Antibodies

[0132] Insulin-like growth factor 1 receptor is a transmembrane protein found on the surface of human cells activated by insulin-like growth factor 1 (IGF-1) and 2 (IGF-2). In some embodiments, radioimmunoconjugates comprise antibodies against insulin-like growth factor-1 receptor (IGF-1R). Although not a typical oncogene, IGF-1R promotes initiation and progression of cancer, playing a critical role in mitogenic transformation and maintenance of the transformed phenotype. IGF-1R has been associated with development of multiple common cancers including breast, lung (e.g., non-small lung), liver, prostate, pancreas, ovarian, colon, melanoma, adrenocortical carcinoma, and various types of sarcomas. IGF-1R signaling stimulates tumour cell proliferation and metabolism, supports angiogenesis, and confers protection from apoptosis. It affects metastatic factors (e.g., HIF-1 dependent hypoxia signaling), anchorage independent growth, as well as growth and survival of tumour metastases after extravasation. IGF-1R has also been implicated in the development, maintenance and enrichment of therapeutic resistant cancer stem cell populations.

[0133] Despite the abundance of data implicating IGF-1R's role in cancer, therapeutics targeting IGF-1R have yet to demonstrate a significant impact on disease. There has been much speculation for this lack of efficacy including the inability to identify appropriate biomarkers for patient identification, complexity and interdependency of the IGF-1/IR signaling pathway and the development of other growth hormone compensatory mechanisms [Beckwith and Yee, *Mol Endocrinol*, November 2015, 29(11):1549-1557]. Radioimmunotherapy, however, may provide a viable mechanism for treating cancers overexpressing the IGF-1 receptor by utilizing the ability of IGF-1R to undergo antibody triggered internalization and lysosomal degradation to deliver targeted radioisotopes inside cancer cells. Internalization and lysosomal degradation of an IGF-1R targeted radioimmunoconjugate prolongs the residence time of the delivered radioisotope inside cancer cells, thereby maximizing the potential for a cell killing emission to occur. In the case of actinium-225, which yields 4 alpha particles per decay chain, cell death can be accomplished by as little as 1 atom of radionuclide delivered per cell [Sgouros, et al. *J Nucl Med*. 2010, 51:311-2]. Cell killing due to direct DNA impact and breakage by an alpha particle may occur in the targeted cell or in a radius of 2 or 3 non-targeted cells for a given alpha particle decay. In addition to having very high potential anti-tumour potency, IGF-1R targeted radioimmunoconjugates may not generate mechanistic resistance as they do not rely on blocking ligand binding to the receptor to inhibit the oncologic process, as needed with a therapeutic antibody.

[0134] Several IGF-1R antibodies have been developed and investigated for the treatment of various types of cancers, including figitumumab, cixutumumab, ganitumab, AVE1642 (also known as humanized EM164 and huEM164), BII002, robatumumab, and teprotumumab. After binding to IGF-1R, these antibodies are internalized into the cell and degraded by lysosomal enzymes. The combination of overexpression on tumor cells and internalization offers the possibility of delivering detection agents directly to the tumor site while limiting the exposure of normal tissues to toxic agents.

[0135] The CDRs of the light chain variable region of AVE1642 have the sequences:

(CDR-L1)	SEQ ID NO: 1
RSSQSIVHSNVNTYLE	
(CDR-L2)	SEQ ID NO: 2
KVSNRFS	
(CDR-L3)	SEQ ID NO: 3
FQGSHPPT	

[0136] The light chain variable region of AVE1642 has the sequence:

	SEQ ID NO: 4
DVVMTQTPLSLPVLGDPASISCRSSQSIVHSNVNTYLEWYLQKPGQSP	
RLLIYKVSNRFSVGPDRFSGSGAGTDFTLRISRVEAEDLGIYYCFQGS	

-continued

VPPTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPR
EAK

[0137] The CDRs of the heavy chain variable region of AVE1642 have the sequences:

(CDR-H1)	SEQ ID NO: 5
SYWMH	
(CDR-H2)	SEQ ID NO: 6
GEINPSNGRTNYNQKFGQ	
(CDR-H3)	SEQ ID NO: 7
GRPDYYGSSKWFYFDV	

[0138] The heavy chain variable region of AVE1642 has the sequence:

	SEQ ID NO: 8
QVQLVQSGAEVVKPGASVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIG	
INPSNGRTNYNQKFGQKATLTVDKSSSTAYMQLSSLTSEDSAVYYFARGR	
PDYYGSSKWFYFDVWGQGTITVTVSSASTKGPSVFPPLAPSSKSTSGGTAALG	

[0139] Endosialin (TEM-1) Antibodies

[0140] Endosialin, also known as TEM-1 or CD-248, is an antigen expressed by tumor-associated endothelial cells, stromal cells, and pericytes.

[0141] Examples of endosialin antibodies include hMP-E-8.3 (disclosed in WO 2017/134234, the entire contents of which are incorporated by reference herein) and ontuxizumab (MORAb-004).

[0142] In some embodiments, the endosialin antibody or antigen-binding fragment thereof recognizes an epitope having an amino acid sequence of SRDHQIPVIAAN (SEQ ID NO: 9).

[0143] In some embodiments, the heavy chain variable region of the endosialin antibody or antibody-binding fragment thereof comprises the complementarity determining regions (CDRs) having the following sequences:

CDR-H1 :	(SEQ ID NO: 10)
GYGVN	
or	
GFSLTGYGVN	(SEQ ID NO: 11)
CDR-H2 :	(SEQ ID NO: 12)
MIWVDGSTDYNSALKS	
CDR-H3 :	(SEQ ID NO: 13)
GGYGAMDY	

[0144] In some embodiments, the light chain variable region of the endosialin antibody or antibody-binding fragment thereof comprises the complementarity determining regions (CDRs) having the following sequences:

CDR-L1: (SEQ ID NO: 14)
 HASQININVWLT
 CDR-L2: (SEQ ID NO: 15)
 KASNLHT
 CDR-L3: (SEQ ID NO: 16)
 QQGQSYJWT

[0145] In some embodiments, the endosialin antibody or antigen-binding fragment thereof is a humanized antibody.

[0146] In some embodiments, the heavy chain variable region of the endosialin antibody or antigen-binding fragment thereof comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 17, 18, 19, or 20:

Humanized VH1: (SEQ ID NO: 17)
 QVQLQESGPGLVKPKSETLSLTCTVSGFSLTGYGVNWIROPKGLLEWIG
 MIWVDGSTDYNSALKSRVTISVDTSKNQFSLKLSVTAADTAVYYCARG
 GYGAMDYWGQGLTLTVSS

Humanized VH2: (SEQ ID NO: 18)
 QVQLQESGPGLVKPKSETLSLTCTVSGFSLTGYGVNWIROPKGLLEWIG
 MIWVDGSTDYNSALKSRVTISVDTSKNQFSLKLSVTAADTAVYYCARG
 GYGAMDYWGQGLTLTVSS

Humanized VH3: (SEQ ID NO: 19)
 QLQLQESGPGLVKPKSETLSLTCTVSGFSLTGYGVNWIROPKGLLEWIG
 MIWVDGSTDYNSALKSRVTISVDTSKNQFSLKLSVTAADTAVYYCARG
 GYGAMDYWGQGLTLTVSS

Humanized VH4: (SEQ ID NO: 20)
 QLQLQESGPGLVKPKSETLSLTCTVSGFSLTGYGVNWIROPKGLLEWIG
 MIWVDGSTDYNSALKSRVTISVDTSKNQFSLKLSVTAADTAVYYCARG
 GYGAMDYWGQGLTLTVSS

In some embodiments, the light chain variable region of the endosialin antibody or antigen-binding fragment thereof comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 21, 22, 23, or 24:

Humanized VL1: (SEQ ID NO: 21)
 DIQMTQSPSSVSASVGDRTVITCHASQININVLTWYQQKPKGKAPKLLIYK
 ASNLHTGVPSPRFGSGSGTDFTLTISLQPEDFATYYCQQGQSYJWTFGG
 GTKLEIK

Humanized VL2: (SEQ ID NO: 22)
 DIQMTQSPSTLSASVGDRTVITCHASQININVLTWYQQKPKGKAPKLLIYK
 ASNLHTGVPSPRFGSGSGTEFTLTISLQPEDFATYYCQQGQSYJWTFGG
 GTKLEIK

Humanized VL3: (SEQ ID NO: 23)
 DIQMTQSPSSLSASVGDRTVITCHASQININVLTWYQQKPKGKAPKLLIYK
 ASNLHTGVPSPRFGSGSGTDFTFITISLQPEDIATYYCQQGQSYJWTFGG
 GTKLEIK

Humanized VL4: (SEQ ID NO: 24)
 DIQMTQSPSSLSASVGDRTVITCHASQININVLTWYQQKPEKAPKSLIYK
 ASNLHTGVPSPRFGSGSGTDFTLTISLQPEDFATYYCQQGQSYJWTFGG
 GTKLEIK

[0147] Nanobodies

[0148] Nanobodies are antibody fragments consisting of a single monomeric variable antibody domain. Nanobodies

may also be referred to as single-domain antibodies. Like antibodies, nanobodies bind selectively to a specific antigen. Nanobodies may be heavy-chain variable domains or light chain domains. Nanobodies may occur naturally or be the product of biological engineering. Nanobodies may be biologically engineered by site-directed mutagenesis or mutagenic screening (e.g., phage display, yeast display, bacterial display, mRNA display, ribosome display).

[0149] Affibodies

[0150] Affibodies are polypeptides or proteins engineered to bind to a specific antigen. As such, affibodies may be considered to mimic certain functions of antibodies. Affibodies may be engineered variants of the B-domain in the immunoglobulin-binding region of staphylococcal protein A. Affibodies may be engineered variants of the Z-domain, a B-domain that has lower affinity for the Fab region. Affibodies may be biologically engineered by site-directed mutagenesis or mutagenic screening (e.g., phage display, yeast display, bacterial display, mRNA display, ribosome display).

[0151] Affibody molecules showing specific binding to a variety of different proteins (e.g. insulin, fibrinogen, transferrin, tumor necrosis factor- α , IL-8, gp120, CD28, human serum albumin, IgA, IgE, IgM, HER2 and EGFR) have been generated, demonstrating affinities (K_d) in the μ M to pM range.

[0152] Fibronectin Type III Domains

[0153] The Fibronectin type III domain is an evolutionarily conserved protein domain found in a wide-variety of extracellular proteins. The Fibronectin type III domain has been used as a molecular scaffold to produce molecules capable of selectively binding a specific antigen. Variants of the Fibronectin type III domains (FN3) that have been engineered for selective-binding may also be referred to as monobodies. FN3 domains may be biologically engineered by site-directed mutagenesis or mutagenic screening (e.g., CIS-display, phage display, yeast display, bacterial display, mRNA display, ribosome display).

[0154] Modified Polypeptides

[0155] Polypeptides used in accordance with the disclosure may have a modified amino acid sequence. Modified polypeptides may be substantially identical to the corresponding reference polypeptide (e.g., the amino acid sequence of the modified polypeptide may have at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the amino acid sequence of the reference polypeptide). In certain embodiments, the modification does not destroy significantly a desired biological activity (e.g., binding to IGF-1R or to endosialin). The modification may reduce (e.g., by at least 5%, 10%, 20%, 25%, 35%, 50%, 60%, 70%, 75%, 80%, 90%, or 95%), may have no effect, or may increase (e.g., by at least 5%, 10%, 25%, 50%, 100%, 200%, 500%, or 1000%) the biological activity of the original polypeptide. The modified polypeptide may have or may optimize a characteristic of a polypeptide, such as in vivo stability, bioavailability, toxicity, immunological activity, immunological identity, and conjugation properties.

[0156] Modifications include those by natural processes, such as post-translational processing, or by chemical modification techniques known in the art. Modifications may occur anywhere in a polypeptide including the polypeptide backbone, the amino acid side chains and the amino- or carboxy-terminus. The same type of modification may be

present in the same or varying degrees at several sites in a given polypeptide, and a polypeptide may contain more than one type of modification. Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from post-translational natural processes or may be made synthetically. Other modifications include pegylation, acetylation, acylation, addition of acetamidomethyl (Acm) group, ADP-ribosylation, alkylation, amidation, biotinylation, carbamoylation, carboxyethylation, esterification, covalent attachment to flavin, covalent attachment to a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of drug, covalent attachment of a marker (e.g., fluorescent or radioactive), covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent crosslinks, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation and ubiquitination.

[0157] A modified polypeptide can also include an amino acid insertion, deletion, or substitution, either conservative or non-conservative (e.g., D-amino acids, desamino acids) in the polypeptide sequence (e.g., where such changes do not substantially alter the biological activity of the polypeptide). In particular, the addition of one or more cysteine residues to the amino or carboxy-terminus of a polypeptide can facilitate conjugation of these polypeptides by, e.g., disulfide bonding. For example, a polypeptide can be modified to include a single cysteine residue at the amino-terminus or a single cysteine residue at the carboxy-terminus. Amino acid substitutions can be conservative (i.e., wherein a residue is replaced by another of the same general type or group) or non-conservative (i.e., wherein a residue is replaced by an amino acid of another type). In addition, a naturally occurring amino acid can be substituted for a non-naturally occurring amino acid (i.e., non-naturally occurring conservative amino acid substitution or a non-naturally occurring non-conservative amino acid substitution).

[0158] Polypeptides made synthetically can include substitutions of amino acids not naturally encoded by DNA (e.g., non-naturally occurring or unnatural amino acid). Examples of non-naturally occurring amino acids include O-amino acids, N-protected amino acids, an amino acid having an acetylaminoethyl group attached to a sulfur atom of a cysteine, a pegylated amino acid, the omega amino acids of the formula $\text{NH}_2(\text{CH}_2)_n\text{OOH}$ wherein n is 2-6, neutral nonpolar amino acids, such as sarcosine, t-butyl alanine, t-butyl glycine, N-methyl isoleucine, and norleucine. Phenylglycine may substitute for Trp, Tyr, or Phe; citrulline and methionine sulfoxide are neutral nonpolar, cysteic acid is acidic, and ornithine is basic. Proline may be substituted with hydroxyproline and retain the conformation conferring properties.

[0159] Analogs may be generated by substitutional mutagenesis and retain the biological activity of the original polypeptide. Examples of substitutions identified as “conservative substitutions” are shown in Table 1. If such substitutions result in a change not desired, then other type of

substitutions, denominated “exemplary substitutions” in Table 1, or as further described herein in reference to amino acid classes, are introduced and the products screened.

TABLE 1

Amino acid substitutions		
Original residue	Exemplary substitution	Conservative substitution
Ala (A)	Val, Leu, Ile	Val
Arg (R)	Lys, Gln, Asn	Lys
Asn (N)	Gln, His, Lys, Arg	Gln
Asp (D)	Glu	Glu
Cys (C)	Ser	Ser
Gln (Q)	Asn	Asn
Glu (E)	Asp	Asp
Gly (G)	Pro	Pro
His (H)	Asn, Gln, Lys, Arg	Arg
Ile (I)	Leu, Val, Met, Ala, Phe, norleucine	Leu
Leu (L)	Norleucine, Ile, Val, Met, Ala, Phe	Ile
Lys (K)	Arg, Gln, Asn	Arg
Met (M)	Leu, Phe, Ile	Leu
Phe (F)	Leu, Val, Ile, Ala	Leu
Pro (P)	Gly	Gly
Ser (S)	Thr	Thr
Thr (T)	Ser	Ser
Trp (W)	Tyr	Tyr
Tyr (Y)	Trp, Phe, Thr, Ser	Phe
Val (V)	Ile, Leu, Met, Phe, Ala, norleucine	Leu

[0160] Substantial modifications in function or immunological identity are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain.

[0161] Chelating moieties and metal complexes thereof.

[0162] Chelating Moieties

[0163] Examples of suitable chelating moieties include, but are not limited to, DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid), DOTMA (1R,4R,7R,10R)- α , α' , α'' , α''' -tetramethyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid, DOTAM (1,4,7,10-tetrakis(carbamoylmethyl)-1,4,7,10-tetraazacyclododecane),

DOTPA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra propionic acid), DO3AM-acetic acid (2-(4,7,10-tris(2-amino-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid), DOTA-GA anhydride (2,2',2''-(10-(2,6-dioxotetrahydro-2H-pyran-3-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)tri-acetic acid, DOTP (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra(methylene phosphonic acid)), DOTMP (1,4,6,10-tetraazacyclododecane-1,4,7,10-tetramethylene phosphonic acid, DOTA-4AMP (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(acetamido-methylenephosphonic acid), CB-TE2A (1,4,8,11-tetraazabicyclo[6.6.2]hexadecane-4,11-diacetic acid), NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid), NOTP (1,4,7-triazacyclononane-1,4,7-tri(methylene phosphonic acid), TETPA (1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetrapropionic acid), TETA (1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetra acetic acid), HEHA (1,4,7,10,13,16-hexaazacyclohexadecane-1,4,7,10,13,16-hexaacetic acid), PEPA (1,4,7,10,13-pentaazacyclopentadecane-N,N',N'',N''',N''''-pentaacetic acid), H₄octapa (N,N'-bis(6-carboxy-2-pyridylmethyl)-ethylenediamine-N,N'-diacetic acid), H₂dedpa (1,2-[[6-(carboxy)pyridin-2-yl]-methylamino]ethane), H₆phospa (N,N'-(meth-

ylenephosphonate)-N,N'-[6-(methoxycarbonyl)pyridin-2-yl]-methyl-1,2-diaminoethane), TTHA (triethylenetetramine-N,N,N',N'',N''', N''''-hexaacetic acid), DO2P (tetraazacyclododecane dimethanephosphonic acid), HP-DO3A (hydroxypropyltetraazacyclododecanetriacetic acid), EDTA (ethylenediaminetetraacetic acid), Deferoxamine, DTPA (diethylenetriaminepentaacetic acid), DTPA-BMA (diethylenetriaminepentaacetic acid-bismethylamide), HOPO (octadentate hydroxypyridinones), or porphyrins.

[0164] In some embodiments, radioimmunoconjugates comprise a metal complex of a chelating moiety. For example, chelating groups may be used in metal chelate combinations with metals, such as manganese, iron, and gadolinium and isotopes (e.g., isotopes in the general energy range of 60 to 4,000 keV), such as any of the radioisotopes and radionuclides discussed herein^{2, 22}.

[0165] In some embodiments, chelating moieties are useful as detection agents, and radioimmunoconjugates comprising such detectable chelating moieties can therefore be used as diagnostic or theranostic agents.

[0166] Radioisotopes and Radionuclides

[0167] In some embodiments, the metal complex comprises a radionuclide. Examples of suitable radioisotopes and radionuclides include, but are not limited to, ³H, ¹⁴C, ¹⁵N, ¹⁸F, ³⁵S, ⁴⁷Sc, ⁵⁵Co, ⁶⁰Cu, ⁶¹Cu, ⁶²Cu, ⁶⁴Cu, ⁶⁶Ga, ⁶⁷Ga, ⁶⁷Cu, ⁶⁸Ga, ⁷⁵Br, ⁷⁶Br, ⁷⁷Br, ⁸²Rb, ⁸⁹Zr, ⁸⁶Y, ⁸⁷Y, ⁹⁰Y, ⁹⁷Ru, ⁹⁹Tc, ^{99m}Tc, ¹⁰⁵Rh, ¹⁰⁹Pd, ¹¹¹In, ¹²³I, ¹²⁴I, ¹²⁵I, ¹³¹I, ¹⁴⁹Pm, ¹⁴⁹Tb, ¹⁵³Sm, ¹⁶⁶Ho, ¹⁷⁷Lu, ^{117m}Sn, ¹⁸⁶Re, ¹⁸⁸Re, ¹⁹⁸Au, ¹⁹⁹Au, ²⁰¹Tl, ²⁰³Pb, ²¹¹At, ²¹²Pb, ²¹²Bi, ²¹³Bi, ²²³Ra, ²²⁵Ac, ²²⁷Th, and ²²⁹Th.

[0168] In some embodiments, the radionuclide is an alpha emitter, e.g., Astatine-211 (²¹¹At), Bismuth-212 (²¹²Bi), Bismuth-213 (²¹³Bi), Actinium-225 (²²⁵Ac), Radium-223 (²²³Ra), Lead-212 (²¹²Pb), Thorium-227 (²²⁷Th), or Terbium-149 (¹⁴⁹Tb).

[0169] Linkers

[0170] In some embodiments, the linker is as shown within the structure of Formula I-b, as that part of Formula I-b absent A and B:



(A and B are as defined in Formula I-a.)

[0171] Thus, in some embodiments, the linker is $-L^1-(L^2)_n-$

[0172] wherein L^1 is optionally substituted C_1-C_6 alkyl, substituted C_1-C_6 heteroalkyl, substituted aryl or heteroaryl;

[0173] n is 1-5; and

[0174] each L^2 , independently, has the structure:



wherein X^1 is $C=O(NR^1)$, $C=S(NR^1)$, $OC=O(NR^1)$, $NR^1C=O(O)$, $NR^1C=O(NR^1)$, $-CH_2PhC=O(NR^1)$, $-CH_2Ph(NH)C=S(NR^1)$, O , or NR^1 ; and each R^1 independently is H or optionally substituted C_1-C_6 alkyl or optionally substituted C_1-C_6 heteroalkyl, substituted aryl or heteroaryl, in which C_1-C_6 alkyl can be substituted by oxo ($=O$), heteroaryl, or a combination thereof;

L^3 is optionally substituted C_1-C_{50} alkyl or optionally substituted C_1-C_{50} heteroalkyl or C_5-C_{20} polyethylene glycol; Z^1 is CH_2 , $C=O$, $C=S$, $OC=O$, $NR^1C=O$, NR^1 and R^1 is a hydrogen or optionally substituted C_1-C_6 alkyl, pyrrolidine-2,5-dione.

[0175] Cross-Linking Groups

[0176] In some embodiments, radioimmunoconjugates comprise a cross-linking group instead of or in addition to the targeting moiety or therapeutic moiety (e.g., B in Formula I comprises a cross-linking group).

[0177] A cross-linking group is a reactive group that is able to join two or more molecules by a covalent bond. Cross-linking groups may be used to attach the linker and chelating moiety to a therapeutic or targeting moiety. Cross-linking groups may also be used to attach the linker and chelating moiety to a target in vivo. In some embodiments, the cross-linking group is an amino-reactive, methionine reactive or thiol-reactive cross-linking group, or a sortase-mediated coupling. In some embodiments, the amino-reactive or thiol-reactive cross-linking group comprises an activated ester such as a hydroxysuccinimide ester, 2,3,5,6-tetrafluorophenol ester, 4-nitrophenol ester or an imidate, anhydride, thiol, disulfide, maleimide, azide, alkyne, strained alkyne, strained alkene, halogen, sulfonate, haloacetyl, amine, hydrazide, diazine, phosphine, tetrazine, isothiocyanate, or oxaziridine. In some embodiments, the sortase recognition sequence may comprise of a terminal glycine-glycine-glycine (GGG) and/or LPTXG amino acid sequence, where X is any amino acid. A person having ordinary skill in the art will understand that the use of cross-linking groups is not limited to the specific constructs disclosed herein, but rather may include other known cross-linking groups.

[0178] DNA Damage and Repair Inhibitors (DDRi)

[0179] In various embodiments, a DNA Damage and Repair inhibitor (DDRi) is co-administered with a radioimmunoconjugate. DNA repair involves multiple molecular pathways that repair DNA single strand breaks (e.g., the PARP pathway) and double stranded breaks (e.g., BRCA and other genes such as ATR/ATM). PARP inhibition (PARPi) results in a failure of single stranded break repair, which further leads to double stranded breaks. Available PARP inhibitors act through both PARP enzyme inhibition and DNA-trapping. Tumor cells with BRCA and/or PTEN mutations are sensitive to PARPi. ATR inhibition (ATRi) results in a failure to repair double stranded breaks—the accumulation of double stranded breaks results in cell death. These inhibitors act by preventing homologous recombination and non-homologous end joining mechanisms.

[0180] The present disclosure relates to combination therapy with radioimmunoconjugates and DNA Damage and Repair inhibitors. It has been found that this type of combination therapy results in unexpected improvement in the treatment of cancer, especially in cancers that would not be expected to be responsive to the DDRi. In some embodiments, the DDRi is a PARP inhibitor (PARPi). In some embodiments, the PARPi is selected from the group comprising: niperib, niraparib, olaparib, pamiparib, rucaparib (camsylate), talazoparib, veliparib, or an analog thereof. In some embodiments, the DDRi is an ATM/ATR inhibitor. In some embodiments, the ATM/ATR inhibitor is selected from the group comprising AZ20, AZD0156, AZD1390, AZD6738, BAY-1895344, EPT-46464, M3541, M4344, M6620 (formerly known as VE-922 or VX-970), NU6027, VE-821, or an analog thereof. In some embodiments, the PARPi is adavosertib, AZD2811, or an analog thereof. In some embodiments, the DDRi is a WEE1 inhibitor, a Chk1 inhibitor, or a Chk2 inhibitor. In some embodiments, the DDRi is a DNA-dependent protein kinase (DNA-PK) inhibitor. Non-limiting examples of DNA-PK inhibitors include

AZD7648, KU-0060648, NU7026, NU7441 (KU-57788), PI-103, PIK-75 HCl, PP121, SF2523, and analogs thereof.

[0181] Subjects

[0182] In some disclosed methods, a therapy (e.g., comprising a therapeutic agent) is administered to a subject. In some embodiments, the subject is a mammal, e.g., a human.

[0183] In some embodiments, the subject has received or is receiving another therapy. For example, in some embodiments, the subject has received or is receiving a radioimmunoconjugate. In some embodiments, the subject has received or is receiving a DNA damage and repair inhibitor (DDRi).

[0184] In some embodiments, the subject has cancer or is at risk of developing cancer. For example, the subject may have been diagnosed with cancer. The cancer may be a primary cancer or a metastatic cancer. Subjects may have any stage of cancer, e.g., stage I, stage II, stage III, or stage IV with or without lymph node involvement and with or without metastases. Provided compositions may prevent or reduce further growth of the cancer and/or otherwise ameliorate the cancer (e.g., prevent or reduce metastases). In some embodiments, the subject does not have cancer but has been determined to be at risk of developing cancer, e.g., because of the presence of one or more risk factors such as environmental exposure, presence of one or more genetic mutations or variants, family history, etc. In some embodiments, the subject has not been diagnosed with cancer.

[0185] In some embodiments, the cancer is a solid tumor.

[0186] In some embodiments, the solid tumor cancer is breast cancer, non-small cell lung cancer, small cell lung cancer, pancreatic cancer, head and neck cancer, prostate cancer, colorectal cancer, sarcoma, adrenocortical carcinoma, neuroendocrine cancer, Ewing's Sarcoma, multiple myeloma, or acute myeloid leukemia.

[0187] In some embodiments, the cancer is a non-solid (e.g., liquid (e.g., hematologic)) cancer.

[0188] Administration and Dosage

[0189] Effective and Lower Effective Doses

[0190] The present disclosure provides combination therapies in which the amounts of each therapeutic may or may not be, on their own, therapeutically effective. For example, provided are methods comprising administering a first therapy and a second therapy in amounts that together are effective to treat or ameliorate a disorder, e.g., cancer. In some embodiments, at least one of the first and second therapy is administered to the subject in a lower effective dose. In some embodiments, both the first and the second therapies are administered in lower effective doses.

[0191] In some embodiments, the first therapy comprises a radioimmunoconjugate and the second therapy comprises a DNA damage response inhibitor (DDRi).

[0192] In some embodiments, the first therapy comprises a DDRi and the second therapy comprises a radioimmunoconjugate.

[0193] In some embodiments, therapeutic combinations as disclosed herein are administered to a subject in a manner (e.g., dosing amount and timing) sufficient to cure or at least partially arrest the symptoms of the disorder and its complications. In the context of a single therapy (a "monotherapy"), an amount adequate to accomplish this purpose is defined as a "therapeutically effective amount," an amount of a compound sufficient to substantially improve at least one symptom associated with the disease or a medical condition. The "therapeutically effective amount" typically

varies depending on the therapeutic. For known therapeutic agents, the relevant therapeutically effective amounts may be known to or readily determined by those of skill in the art.

[0194] For example, in the treatment of cancer, an agent or compound that decreases, prevents, delays, suppresses, or arrests any symptom of the disease or condition would be therapeutically effective. A therapeutically effective amount of an agent or compound is not required to cure a disease or condition but will provide a treatment for a disease or condition such that the onset of the disease or condition is delayed, hindered, or prevented, or the disease or condition symptoms are ameliorated, or the term of the disease or condition is changed or, for example, is less severe or recovery is accelerated in an individual. For example, a treatment may be therapeutically effective if it causes a cancer to regress or to slow the cancer's growth.

[0195] The dosage regimen (e.g., amounts of each therapeutic, relative timing of therapies, etc.) that is effective for these uses may depend on the severity of the disease or condition and the weight and general state of the subject. For example, the therapeutically effective amount of a particular composition comprising a therapeutic agent applied to mammals (e.g., humans) can be determined by the ordinarily-skilled artisan with consideration of individual differences in age, weight, and the condition of the mammal. Because certain conjugates of the present disclosure exhibit an enhanced ability to target cancer cells and residualize, the dosage of these compounds can be lower than (e.g., less than or equal to about 90%, 75%, 50%, 40%, 30%, 20%, 15%, 12%, 10%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, or 0.1% of) the equivalent dose of required for a therapeutic effect of the unconjugated agent. Therapeutically effective and/or optimal amounts can also be determined empirically by those of skill in the art. Thus, lower effective doses can also be determined by those of skill in the art.

[0196] Single or multiple administrations of a composition (e.g., a pharmaceutical composition comprising a therapeutic agent) can be carried out with dose levels and pattern being selected by the treating physician. The dose and administration schedule can be determined and adjusted based on the severity of the disease or condition in the subject, which may be monitored throughout the course of treatment according to the methods commonly practiced by clinicians or those described herein.

[0197] In the disclosed combination therapy methods, the first and second therapies may be administered sequentially or concurrently to a subject. For example, a first composition comprising a first therapeutic agent and a second composition comprising a second therapeutic agent may be administered sequentially or concurrently to a subject. Alternatively or additionally, a composition comprising a combination of a first therapeutic agent and a second therapeutic agent may be administered to the subject.

[0198] In some embodiments, the radioimmunoconjugate is administered in a single dose. In some embodiments, the radioimmunoconjugate is administered more than once. When the radioimmunoconjugate is administered more than once, the dose of each administration may be the same or different.

[0199] In some embodiments, the DDRi is administered in a single dose. In some embodiments, the DDRi is administered more than once, e.g., at least twice, at least three times, etc. In some embodiments, the DDRi is administered multiple times according to a regular or semi-regular schedule,

e.g., once every approximately two weeks, once a week, twice a week, three times a week, or more than three times a week. When the DDRi is administered more than once, the dose of each administration may be the same or different. For example, the DDRi may be administered in an initial dose amount, and then subsequent dosages of the DDRi may be higher or lower than the initial dose amount.

[0200] In some embodiments, the first dose of the DDRi is administered at the same time as the first dose of the radioimmunoconjugate. In some embodiments, the first dose of the DDRi is administered before the first dose of radioimmunoconjugate. In some embodiments, the first dose of the DDRi is administered after the first dose of radioimmunoconjugate. In some embodiments, subsequent doses of the DDRi are administered.

[0201] In some embodiments, radioimmunoconjugates (or a composition thereof) and DDRis (or a composition thereof) are administered within 28 days (e.g., within 14, 7, 6, 5, 4, 3, 2, or 1 day(s)) of each other.

[0202] In some embodiments, radioimmunoconjugates (or a composition thereof) and DDRis (or a composition thereof) are administered within 90 days (e.g., within 80, 70, 60, 50, 40, 30, 20, 10, 5, 4, 3, 2, or 1 day(s)) of each other. In various embodiments the DDRi is administered at the same time as radioimmunoconjugate. In various embodiments, the DDRi is administered multiple times after the first administration of radioimmunoconjugate.

[0203] In some embodiments, compositions (such as compositions comprising radioimmunoconjugates) are administered for radiation treatment planning or diagnostic purposes. When administered for radiation treatment planning or diagnostic purposes, compositions may be administered to a subject in a diagnostically effective dose and/or an amount effective to determine the therapeutically effective dose.

[0204] In some embodiments, a first dose of disclosed conjugate or a composition (e.g., pharmaceutical composition) thereof is administered in an amount effective for radiation treatment planning, followed administration of a combination therapy including a conjugate as disclosed herein and another therapeutic.

[0205] Pharmaceutical compositions comprising one or more agents (e.g., radioimmunoconjugates and/or DDRis) can be formulated for use in accordance with disclosed methods and systems in a variety of drug delivery systems. One or more physiologically acceptable excipients or carriers can also be included in the composition for proper formulation. Examples of suitable formulations are found in *Remington's Pharmaceutical Sciences*, Mack Publishing Company, Philadelphia, Pa., 17th ed., 1985. For a brief review of methods for drug delivery, see, e.g., Langer (Science 249:1527-1533, 1990).

[0206] Formulations

[0207] Pharmaceutical compositions may be formulated for parenteral, intranasal, topical, oral, or local administration, such as by a transdermal means, for prophylactic and/or therapeutic treatment. Pharmaceutical compositions can be administered parenterally (e.g., by intravenous, intramuscular, or subcutaneous injection), or by oral ingestion, or by topical application or intraarticular injection at areas affected by the vascular or cancer condition. Examples of additional routes of administration include intravascular, intra-arterial, intratumor, intraperitoneal, intraventricular, intrathecal, as well as nasal, ophthalmic, intrascleral, intraorbital, rectal,

topical, or aerosol inhalation administration. Also specifically contemplated are sustained release administration, by such means as depot injections or erodible implants or components. Suitable compositions include compositions comprising include agents (e.g., compounds as disclosed herein) dissolved or suspended in an acceptable carrier, preferably an aqueous carrier, e.g., water, buffered water, saline, or PBS, among others, e.g., for parenteral administration. Compositions may contain pharmaceutically acceptable auxiliary substances to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents, or detergents, among others. In some embodiments, compositions are formulated for oral delivery; for example, compositions may contain inert ingredients such as binders or fillers for the formulation of a unit dosage form, such as a tablet or a capsule. In some embodiments, compositions are formulated for local administration; for example, compositions may contain inert ingredients such as solvents or emulsifiers for the formulation of a cream, an ointment, a gel, a paste, or an eye drop.

[0208] Compositions may be sterilized, e.g., by conventional sterilization techniques, or sterile filtered. Aqueous solutions may be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration. The pH of the preparations typically will be between 3 and 11, more preferably between 5 and 9 or between 6 and 8, and most preferably between 6 and 7, such as 6 to 6.5. In some embodiments, compositions in solid form are packaged in multiple single dose units, each containing a fixed amount of the above-mentioned agent or agents, such as in a sealed package of tablets or capsules. In some embodiments, compositions in solid form are packaged in a container for a flexible quantity, such as in a squeezable tube designed for a topically applicable cream or ointment.

[0209] Other Agents

[0210] In some embodiments, disclosed methods further include administering an antiproliferative agent, radiation sensitizer, or an immunoregulatory or immunomodulatory agent.

[0211] By "antiproliferative" or "antiproliferative agent," as used interchangeably herein, is meant any anticancer agent, including those antiproliferative agents listed in Table 2, any of which can be used in combination with a radioimmunoconjugate to treat a condition or disorder. Antiproliferative agents also include organo-platinum derivatives, naphthoquinone and benzoquinone derivatives, chrysophanic acid and anthroquinone derivatives thereof.

[0212] By "immunoregulatory agent" or "immunomodulatory agent," as used interchangeably herein, is meant any immuno-modulator, including those listed in Table 2, any of which can be used in combination with a radioimmunoconjugate.

[0213] As used herein, "radiation sensitizer" includes any agent that increases the sensitivity of cancer cells to radiation therapy. Radiation sensitizers may include, but are not limited to, 5-fluorouracil, analogs of platinum (e.g., cisplatin, carboplatin, oxaliplatin), gemcitabine, EGFR antagonists (e.g., cetuximab, gefitinib), farnesyltransferase inhibitors, COX-2 inhibitors, bFGF antagonists, and VEGF antagonists.

TABLE 2

Alkylating agents	Busulfan	Chlorambucil
	dacarbazine	procarbazine
	ifosfamide	altretamine
	hexamethylmelamine	estramustine phosphate
	thiotepa	mechlorethamine
	dacarbazine	streptozocin
	lomustine	temozolomide
	cyclophosphamide	Semustine
	spiroplatin	lobaplatin (Aeterna)
	tetraplatin	satraplatin (Johnson Matthey)
Platinum agents	ormaplatin	BBR-3464 (Hoffmann-La Roche)
	iproplatin	Miriaplatin
	picoplatin	AP-5280 (Access)
	oxaliplatin	cisplatin
	carboplatin	
	azacytidine	trimetrexate
	Floxuridine	deoxycoformycin
	2-chlorodeoxyadenosine	pentostatin
	6-mercaptopurine	hydroxyurea
	6-thioguanine	decitabine (SuperGen)
Antimetabolites	cytarabine	clofarabine (Bioenvision)
	2-fluorodeoxy cytidine	irofulven (MGI Pharma)
	methotrexate	DMDC (Hoffmann-La Roche)
	tomudex	ethynylecytidine (Taiho)
	fludarabine	gemcitabine
	raltitrexed	capecitabine
	amsacrine	exatecan mesylate (Daiichi)
	epirubicin	quinamed (ChemGenex)
	etoposide	gimatecan (Sigma-Tau)
	teniposide or mitoxantrone	diflomotecan (Beaufour-Ipsen)
Topoisomerase inhibitors	7-ethyl-10-hydroxy-camptothecin	TAS-103 (Taiho)
	dexrazoxanet (TopoTarget)	elsamitucin (Spectrum)
	pixantrone (Novuspharma)	Edotecarin
	rebeccamycin analogue (Exelixis)	Cositecan
	BBR-3576 (Novuspharma)	Belotecan
	rubitecan (SuperGen)	hydroycamptothecin (SN-38)
	irinotecan (CPT-11)	
	topotecan	azonafide
	valrubicin	anthrapyrazole
	therarubicin	oxantrazole
Antitumor antibiotics	idarubicin	losoxantrone
	rubidazole	Sabarubicin
	plicamycin	Epirubicin
	porfiromycin	mitoxantrone
	mitoxantrone (novantrone)	doxorubicin
	amonafide	E7010 (Abbott)
	colchicine	PG-TXL (Cell Therapeutics)
	vinblastine	IDN 5109 (Bayer)
	vindesine	A 105972 (Abbott)
	dolastatin 10 (NCI)	A 204197 (Abbott)
rhizoxin (Fujisawa)	LU 223651 (BASF)	
Antimitotic agents	mivobulin (Wamer-Lambert)	D 24851 (ASTAMedica)
	cemadotin (BASF)	ER-86526 (Eisai)
	RPR 109881A (Aventis)	combretastatin A4 (BMS)
	TXD 258 (Aventis)	isohomohalichondrin-B (PharmaMar)
	epothilone B (Novartis)	ZD 6126 (AstraZeneca)
	T 900607 (Tularik)	AZ10992 (Asahi)
	T 138067 (Tularik)	IDN-5109 (Indena)
	cryptophycin 52 (Eli Lilly)	AVLB (Prescient NeuroPharma)
	vinflunine (Fabre)	azaepothilone B (BMS)
	auristatin PE (Teikoku Hormone)	BNP-7787 (BioNumerik)
BMS 247550 (BMS)	CA-4 prodrug (OXiGENE)	
BMS 184476 (BMS)	dolastatin-10 (NIH)	
BMS 188797 (BMS)	CA-4 (OXiGENE)	
taxoprexin (Protarga)	docetaxel	
SB 408075 (GlaxoSmithKline)	vincristine	
Aromatase inhibitors	Vinorelbine	paclitaxel
	Trichostatin A	YM-511 (Yamanouchi)
	aminoglutethimide	fomestane
	atamestane (BioMedicines)	exemestane
	letrozole	
	anastrozole	nolatrexed (Eximias)
	pemetrexed (Eli Lilly)	CoFactor™ (BioKeys)
	ZD-9331 (BTG)	edotretotide (Novartis)
	trabectedin (PharmaMar)	mafosfamide (Baxter International)
	glufosfamide (Baxter International)	apaziquone (Spectrum)
DNA antagonists	albumin + 32P (Isotope Solutions)	

TABLE 2-continued

	thymectacin (NewBiotics)	Pharmaceuticals)
Farnesyltransferase inhibitors	arglabin (NuOncology Labs)	O6 benzyl guanine (Paligent)
	lonafarnib (Schering-Plough)	tipifarnib (Johnson & Johnson)
Pump inhibitors	BAY-43-9006 (Bayer)	perillyl alcohol (DOR BioPharma)
	CBT-1 (CBA Pharma)	zosuquidar trihydrochloride (Eli Lilly)
Histone acetyltransferase inhibitors	tariquidar (Xenova)	biricodar dicitrate (Vertex)
	MS-209 (Schering AG)	pivaloyloxymethyl butyrate (Titan)
Metalloproteinase inhibitors	tacedinaline (Pfizer)	depsiptide (Fujisawa)
	SAHA (Aton Pharma)	CMT-3 (CollaGenex)
Ribonucleoside reductase inhibitors	MS-275 (Schering AG)	BMS-275291 (Celltech)
TNF alpha agonists/antagonists	Neovastat (Aeterna Laboratories)	tezacitabine (Aventis)
Endothelin A receptor antagonist	marimastat (British Biotech)	didox (Molecules for Health)
Retinoic acid receptor agonists	gallium maltolate (Titan)	revimid (Celgene)
Immuno-modulators	triapine (Vion)	
	virulizin (Lorus Therapeutics)	YM-598 (Yamanouchi)
	CDC-394 (Celgene)	alitretinoin (Ligand)
	atrasentan (Abbott)	dexosome therapy (Anosys)
	ZD-4054 (AstraZeneca)	pentrix (Australian Cancer Technology)
	fenretinide (Johnson & Johnson)	ISF-154 (Tragen)
	LGD-1550 (Ligand)	cancer vaccine (Intercell)
	interferon	norelin (Biostar)
	oncophage (Antigenics)	BLP-25 (Biomira)
	GMK (Progenics)	MGV (Progenics)
	adenocarcinoma vaccine (Biomira)	β -alethine (Dovetail)
	CTP-37 (AVI BioPharma)	CLL therapy (Vasogen)
	IRX-2 (Immuno-Rx)	Ipilimumab (BMS),
	PEP-005 (Peplin Biotech)	CM-10 (cCam Biotherapeutics)
	synchrovax vaccines (CTL Immuno)	atezolizumab (Genentech)
	melanoma vaccine (CTL Immuno)	
	p21 RAS vaccine (GemVax)	dexamethasone
	MAGE-A3 (GSK)	prednisone
	nivolumab (BMS)	methylprednisolone
	abatacept (BMS)	prednisolone
	pembrolizumab (Merck)	aminoglutethimide
	estrogens	leuprolide
Hormonal and antihormonal agents	conjugated estrogens	octreotide
	ethinyl estradiol	mitotane
	chlortrianisen	P-04 (Novogen)
	idenestrol	2-methoxyestradiol (EntreMed)
	hydroxyprogesterone caproate	arzoixifene (Eli Lilly)
	medroxyprogesterone	tamoxifen
	testosterone	toremofine
	testosterone propionate;	goserelin
	fluoxymesterone	Leuporelin
	methyltestosterone	bicalutamide
	diethylstilbestrol	Pd-bacteriophagephorbide (Yeda)
	megestrol	Motexafin lutetium
	bicalutamide	hypericin
	flutamide	
	nilutamide	EKB-569 (Wyeth)
Photodynamic agents	talaporfin (Light Sciences)	kahalide F (PharmaMar)
	Theralux (Theratechnologies)	CEP-701 (Cephalon)
	motexafin gadolinium (Pharmacyclics)	CEP-751 (Cephalon)
Kinase Inhibitors	imatinib (Novartis)	MLN518 (Millenium)
	leflunomide (Sugen/Pharmacia)	PKC412 (Novartis)
	ZD1839 (AstraZeneca)	Phenoxodiol (Novogen)
	erlotinib (Oncogene Science)	C225 (ImClone)
	canertinib (Pfizer)	rhu-Mab (Genentech)
	squalamine (Genaera)	MDX-H210 (Medarex)
	SU5416 (Pharmacia)	2C4 (Genentech)
	SU6668 (Pharmacia)	MDX-447 (Medarex)
	ZD4190 (AstraZeneca)	ABX-EGF (Abgenix)
	ZD6474 (AstraZeneca)	IMC-1C11 (ImClone)
	vatalanib (Novartis)	Tyrophostins
	PKI166 (Novartis)	Gefitinib (Iressa)
	GW2016 (GlaxoSmithKline)	PTK787 (Novartis)
	EKB-509 (Wyeth)	EMD 72000 (Merck)
	trastuzumab (Genentech)	Emodin
	OSI-774 (Tarceva™)	Radicinol
	CI-1033 (Pfizer)	Vemurafenib (B-Raf enzyme inhibitor, Daiichi Sankyo)
	SU11248 (Pharmacia)	
	RH3 (York Medical)	
	Genistein	
	Radicinol	
	Met-MAb (Roche)	

TABLE 2-continued

SR-27897 (CCK A inhibitor, Sanofi-Synthelabo)	ceflatonin (apoptosis promotor, ChemGenex)
tocladesine (cyclic AMP agonist, Ribapharm)	BCX-1777 (PNP inhibitor, BioCryst)
alvocidib (CDK inhibitor, Aventis)	ranpimase (ribonuclease stimulant, Alfacell)
CV-247 (COX-2 inhibitor, Ivy Medical)	galarubicin (RNA synthesis inhibitor, Dong-A)
P54 (COX-2 inhibitor, Phytopharm)	tirapazamine (reducing agent, SRI International)
CapCell™ (CYP450 stimulant, Bavarian Nordic)	N-acetylcysteine (reducing agent, Zambon)
GCS-100 (gal3 antagonist, GlycoGenesys)	R-flurbiprofen (NF-kappaB inhibitor, Encore)
G17DT immunogen (gastrin inhibitor, Apton)	3CPA (NF-kappaB inhibitor, Active Biotech)
efaproxiral (oxygenator, Allos Therapeutics)	seocalcitol (vitamin D receptor agonist, Leo)
PI-88 (heparanase inhibitor, Progen)	131-I-TM-601 (DNA antagonist, TransMolecular)
tesmilifene (histamine antagonist, YM BioSciences)	eflornithine (ODC inhibitor, ILEX Oncology)
histamine (histamine H2 receptor agonist, Maxim)	minodronic acid (osteoclast inhibitor, Yamanouchi)
tiazofurin (IMPDH inhibitor, Ribapharm)	indisulam (p53 stimulant, Eisai)
cilengitide (integrin antagonist, Merck KGaA)	aplidine (PPT inhibitor, PharmaMar)
SR-31747 (1L-1 antagonist, Sanofi-Synthelabo)	gemtuzumab (CD33 antibody, Wyeth Ayerst)
CCI-779 (mTOR kinase inhibitor, Wyeth)	PG2 (hematopoiesis enhancer, Pharmagenesis)
exisulind (PDE V inhibitor, Cell Pathways)	Immunol™ (triclosan oral rinse, Endo)
CP-461 (PDE V inhibitor, Cell Pathways)	triacetylrudine (uridine prodrug, Wellstat)
AG-2037 (GARFT inhibitor, Pfizer)	SN-4071 (sarcoma agent, Signature BioScience)
WX-UK1 (plasminogen activator inhibitor, Wilex)	TransMID-107™ (immunotoxin, KS Biomedix)
PBI-1402 (PMN stimulant, ProMetic LifeSciences)	PCK-3145 (apoptosis promotor, Procyon)
bortezomib (proteasome inhibitor, Millennium)	doranidazole (apoptosis promotor, Pola)
SRL-172 (T cell stimulant, SR Pharma)	CHS-828 (cytotoxic agent, Leo)
TLK-286 (glutathione S transferase inhibitor, Telik)	trans-retinoic acid (differentiator, NIH)
PT-100 (growth factor agonist, Point Therapeutics)	MX6 (apoptosis promotor, MAXIA)
midostaurin (PKC inhibitor, Novartis)	apomine (apoptosis promotor, ILEX Oncology)
bryostatin-1 (PKC stimulant, GPC Biotech)	urocidin (apoptosis promotor, Bioniche)
CDA-II (apoptosis promotor, Everlife)	Ro-31-7453 (apoptosis promotor, La Roche)
SDX-101 (apoptosis promotor, Salmedix)	brostallicin (apoptosis promotor, Pharmacia)
rituximab (CD20 antibody, Genentech)	β-lapachone
carmustine	gelonin
Mitoxantrone	cafestol
Bleomycin	kahweol
Absinthin	caffeic acid
Chrysophanic acid	Tyrphostin AG
Cesium oxides	PD-1 inhibitors
BRAF inhibitors,	CTLA-4 inhibitors
PD-L1 inhibitors	sorafenib
MEK inhibitors	
bevacizumab	
angiogenesis inhibitors	
dabrafenib	

EXAMPLES

Example 1. In Vivo Synergy Study: [²²⁵Ac]-FPI-1434+BAY-1895344—Dosing Schedule 1

[0214] An in vivo synergy study was conducted with [²²¹Ac]-FPI-1434 and BAY-1895344. [²²⁵Ac]-FPI-1434 was given as a single agent at doses sub-optimal for tumor regression (50 nCi) in a Colo-205 (colorectal cancer) xenograft model and (200 nCi) in an A549 (NSCLC) xenograft model. Combination groups (n=5) were dosed with BAY-1895344 (i.p.) 2 days on, 5 days off, using a 20 mg/kg dose for 28 days. The first dose of BAY-1895344 was administered 24 hours following [²²⁵Ac]-FPI-1434 administration. See FIG. 1.

[0215] Relative tumor volume was evaluated up to 28 days after administration. In the both Colo-205 xenograft model and the A549 xenograft model, BAY-1895344 alone did not demonstrate any reduction in reduction in tumor volume over time relative to Vehicle controls. In both models, treatment with [²²⁵Ac]-FPI-1434 alone demonstrated significant reduction in tumor volume relative to Vehicle controls and treatment with BAY-1895344 alone. There did not appear to be any additional benefit, when [²²⁵Ac]-FPI-1434 and BAY-1895344 were administered as a combination

therapy using the dosing schedule in FIG. 1 as compared to either treatment being administered alone. See FIGS. 2a and 2b.

Example 2. In Vivo Synergy Study: FPI-1434+BAY-1895344—Dosing Schedule 2

[0216] An in vivo synergy study was conducted with [²²⁵Ac]-FPI-1434 and BAY-1895344 using a second dosing schedule. FPI-1434 was given as a single agent at doses sub-optimal for tumor regression (50 nCi) in a Colo-205 (colorectal cancer) xenograft model. Combination groups (n=5) were dosed with BAY-1895344 three times a week starting with a 40 mg/kg dose. The dose was gradually reduced to 20 mg/kg due to transient animal somnolence at the higher doses. The first dose of BAY-1895344 was administered 24 hours following FPI-1434 administration. See FIG. 3.

[0217] Relative tumor volume was evaluated up to 28 days after administration. Both [²²⁵Ac]-FPI-1434 and BAY-1895344 alone demonstrated some reduction in tumor volume over time, with [²²⁵Ac]-FPI-1434 being more effective at reducing tumor volume compared to BAY-1895344 alone. When [²²⁵Ac]-FPI-1434 and BAY-1895344 were administered as a combination therapy using the dosing schedule in

FIG. 3, animals demonstrated significantly lower tumor volumes when compared with either treatment alone. See FIG. 4.

Example 3. In Vivo Efficacy of Olaparib as a Single Agent

[0218] An in vivo efficacy study was conducted with olaparib alone as a single agent. Olaparib was given as a single agent at different doses in a Colo-205 (colorectal cancer) xenograft model and in an A549 (NSCLC) xenograft model. Groups of animals (n=5) were dosed with olaparib (i.p.) 5 days on, 2 days off using 10-100 mg/kg doses. See FIG. 5.

[0219] Olaparib showed modest efficacy as a single agent in both models (FIGS. 6A and 6B). There did not appear to be a dose response for either model, and immunohistochemical analysis of γ -H2AX foci showed no increase in DSB formation after olaparib treatment.

Example 4. In Vivo Synergy Study:
FPI-1434+Olaparib—Dosing Schedule 1

[0220] An in vivo synergy study was conducted with [²²⁵Ac]-FPI-1434 and olaparib. [²²⁵Ac]-FPI-1434 was given as a single agent at doses sub-optimal for tumor regression (50 nCi) in a Colo-205 (colorectal cancer) xenograft model and (200 nCi) in an A549 (NSCLC) xenograft model. Combination groups (n=5) were dosed with olaparib (i.p.) 5 days on, 2 days off, using a 50 mg/kg dose for 28 days. Animals were pre-dosed with olaparib 3 times prior to the [²²⁵Ac]-FPI-1434 administration. See FIG. 7.

[0221] Relative tumor volume was evaluated up to 28 days after administration. In the Colo-205 xenograft model, both [²²⁵Ac]-FPI-1434 and olaparib alone demonstrated some reduction in tumor volume over time, with [²²⁵Ac]-FPI-1434 being more effective at reducing tumor volume compared to olaparib alone. There did not appear to be any additional benefit, when [²²⁵Ac]-FPI-1434 and olaparib were administered as a combination therapy using the dosing schedule in FIG. 7 as compared to either treatment being administered alone. See FIG. 8a.

[0222] In the A549 xenograft model, there was no apparent difference in tumor volume over time with treatment of olaparib alone when compared to animals who had received no treatment. [²²⁵Ac]-FPI-1434 had significantly reduced tumor volume when compared to vehicle treated animals, and olaparib treated animals. There did not appear to be any addition benefit, when [²²⁵Ac]-FPI-1434 and olaparib were administered as a combination therapy using the dosing schedule in FIG. 7 as compared to either treatment being administered alone. See FIG. 8b.

Example 5. In Vivo Synergy Study:
FPI-1434+Olaparib—Dosing Schedule 2

[0223] An in vivo synergy study was conducted with [²²⁵Ac]-FPI-1434 and olaparib using a second dosing sched-

ule. FPI-1434 was given as a single agent at doses sub-optimal for tumor regression (50 nCi) in a Colo-205 (colorectal cancer) xenograft model. Combination groups (n=5) were dosed with olaparib (i.p.) 5 days on, 2 days off, using a 50 mg/kg dose for 28 days. The first dose of olaparib was administered 24 hours following FPI-1434 administration. See FIG. 9.

[0224] Relative tumor volume was evaluated up to 28 days after administration. Both [²²⁵Ac]-FPI-1434 and olaparib alone demonstrated significant reduction in tumor volume overtime, with [²²⁵Ac]-FPI-1434 being more effective at reducing tumor volume compared to olaparib alone. When [²²⁵Ac]-FPI-1434 and olaparib were administered as a combination therapy using the dosing schedule in FIG. 9, animals demonstrated significantly lower tumor volumes when compared with either treatment alone. See FIG. 10.

Example 6. In Vivo Synergy Study:
FPI-1434+Olaparib Combination Therapy at
Multiple Dose Levels

[0225] An in vivo study was conducted with [²²⁵Ac]-FPI-1434 and olaparib in a Colo-205 (colorectal cancer) xenograft model, with [²²⁵Ac]-FPI-1434 administered at a dose of 20 nCi, 50 nCi, or 100 nCi. In combination groups (n=5), animals were dosed with olaparib (i.p.) starting at 24 hours after [²²⁵Ac]-FPI-1434 administration according to a 5 days on, 2 days off schedule using 25 or 50 mg/kg doses until day 30 after [²²⁵Ac]-FPI-1434 administration (“day 0”). See FIG. 11.

[0226] Relative tumor volume was evaluated at various time points after administration. FIG. 12 shows results using lower effective doses of [²²⁵Ac]-FPI-1434 (20 nCi) and olaparib (25 mg/kg). Whereas no or limited therapeutic effect was observed with either [²²⁵Ac]-FPI-1434 or olaparib alone, animals that received the combination therapy demonstrated significantly lower tumor volumes when compared with animals that received either treatment alone. FIG. 13A-13C show results using 20 nCi (FIG. 13A), 50 nCi (FIG. 13B), or 100 nCi (FIG. 13C) [²²⁵Ac]-FPI-1434 with olaparib (25 mg/kg or 50 mg/kg). The strongest combination effects were observed at the lowest single agent doses. See FIG. 13A.

[0227] Thus, the present Example demonstrates that the combination of [²²⁵Ac]-FPI-1434 and olaparib, each at lower effective doses, resulted in a synergistic efficacy.

EQUIVALENTS/OTHER EMBODIMENTS

[0228] Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments described herein. Such equivalents are intended to be encompassed by the following claims.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 24
 <210> SEQ ID NO 1
 <211> LENGTH: 16
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence

-continued

```

<220> FEATURE:
<223> OTHER INFORMATION: CDR-L1 of AVE1642

<400> SEQUENCE: 1

Arg Ser Ser Gln Ser Ile Val His Ser Asn Val Asn Thr Tyr Leu Glu
1          5          10          15

<210> SEQ ID NO 2
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: CDR-L2 of AVE1642

<400> SEQUENCE: 2

Lys Val Ser Asn Arg Phe Ser
1          5

<210> SEQ ID NO 3
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: CDR-L3 of AVE1642

<400> SEQUENCE: 3

Phe Gln Gly Ser His Val Pro Pro Thr
1          5

<210> SEQ ID NO 4
<211> LENGTH: 150
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Light chain variable region of AVE1642

<400> SEQUENCE: 4

Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly
1          5          10          15

Asp Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile Val His Ser
20          25          30

Asn Val Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35          40          45

Pro Arg Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
50          55          60

Asp Arg Phe Ser Gly Ser Gly Ala Gly Thr Asp Phe Thr Leu Arg Ile
65          70          75          80

Ser Arg Val Glu Ala Glu Asp Leu Gly Ile Tyr Tyr Cys Phe Gln Gly
85          90          95

Ser His Val Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100         105         110

Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
115         120         125

Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
130         135         140

Tyr Pro Arg Glu Ala Lys
145         150

<210> SEQ ID NO 5

```

-continued

```

<211> LENGTH: 5
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: CDR-H1 of AVE1642

<400> SEQUENCE: 5

Ser Tyr Trp Met His
1           5

<210> SEQ ID NO 6
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: CDR-H2 of AVE1642

<400> SEQUENCE: 6

Gly Glu Ile Asn Pro Ser Asn Gly Arg Thr Asn Tyr Asn Gln Lys Phe
1           5           10           15

Gln Gly

<210> SEQ ID NO 7
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: CDR-H3 for AVE1642

<400> SEQUENCE: 7

Gly Arg Pro Asp Tyr Tyr Gly Ser Ser Lys Trp Tyr Phe Asp Val
1           5           10           15

<210> SEQ ID NO 8
<211> LENGTH: 150
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Heavy chain variable region of AVE1642

<400> SEQUENCE: 8

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Val Lys Pro Gly Ala
1           5           10           15

Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
           20           25           30

Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
           35           40           45

Gly Glu Ile Asn Pro Ser Asn Gly Arg Thr Asn Tyr Asn Gln Lys Phe
           50           55           60

Gln Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
65           70           75           80

Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Phe
           85           90           95

Ala Arg Gly Arg Pro Asp Tyr Tyr Gly Ser Ser Lys Trp Tyr Phe Asp
           100           105           110

Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys
           115           120           125

Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly
130           135           140

```

-continued

Gly Thr Ala Ala Leu Gly
145 150

<210> SEQ ID NO 9
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Epitope for endosialin antibody

<400> SEQUENCE: 9

Ser Arg Asp His Gln Ile Pro Val Ile Ala Ala Asn
1 5 10

<210> SEQ ID NO 10
<211> LENGTH: 5
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: CDR-H1 for endosialin antibody

<400> SEQUENCE: 10

Gly Tyr Gly Val Asn
1 5

<210> SEQ ID NO 11
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: CDR-H1 for endosialin antibody

<400> SEQUENCE: 11

Gly Phe Ser Leu Thr Gly Tyr Gly Val Asn
1 5 10

<210> SEQ ID NO 12
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: CDR-H2 for endosialin antibody

<400> SEQUENCE: 12

Met Ile Trp Val Asp Gly Ser Thr Asp Tyr Asn Ser Ala Leu Lys Ser
1 5 10 15

<210> SEQ ID NO 13
<211> LENGTH: 8
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: CDR-H3 for endosialin antibody

<400> SEQUENCE: 13

Gly Gly Tyr Gly Ala Met Asp Tyr
1 5

<210> SEQ ID NO 14
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: CDR-L1 for endosialin antibody

-continued

<400> SEQUENCE: 14

His Ala Ser Gln Asn Ile Asn Val Trp Leu Thr
 1 5 10

<210> SEQ ID NO 15

<211> LENGTH: 7

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: CDR-L2 for endosialin antibody

<400> SEQUENCE: 15

Lys Ala Ser Asn Leu His Thr
 1 5

<210> SEQ ID NO 16

<211> LENGTH: 9

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: CDR-L3 for endosialin antibody

<400> SEQUENCE: 16

Gln Gln Gly Gln Ser Tyr Pro Trp Thr
 1 5

<210> SEQ ID NO 17

<211> LENGTH: 116

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Humanized VH1 for endosialin antibody

<400> SEQUENCE: 17

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
 1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Gly Tyr
 20 25 30

Gly Val Asn Trp Ile Arg Gln Pro Gly Lys Gly Leu Glu Trp Ile
 35 40 45

Gly Met Ile Trp Val Asp Gly Ser Thr Asp Tyr Asn Ser Ala Leu Lys
 50 55 60

Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
 65 70 75 80

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
 85 90 95

Arg Gly Gly Tyr Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val
 100 105 110

Thr Val Ser Ser
 115

<210> SEQ ID NO 18

<211> LENGTH: 116

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Humanized VH2 for endosialin antibody

<400> SEQUENCE: 18

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu

-continued

```

1           5           10           15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Gly Tyr
      20           25           30
Gly Val Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
      35           40           45
Gly Met Ile Trp Val Asp Gly Ser Thr Asp Tyr Asn Ser Ala Leu Lys
      50           55           60
Ser Arg Val Asn Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu
      65           70           75           80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
      85           90           95
Arg Gly Gly Tyr Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val
      100           105           110
Thr Val Ser Ser
      115

```

```

<210> SEQ ID NO 19
<211> LENGTH: 116
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Humanized VH3 for endosialin antibody

```

```

<400> SEQUENCE: 19

```

```

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1           5           10           15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Gly Tyr
      20           25           30
Gly Val Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
      35           40           45
Gly Met Ile Trp Val Asp Gly Ser Thr Asp Tyr Asn Ser Ala Leu Lys
      50           55           60
Ser Arg Val Thr Ile Ser Val Asp Lys Ser Lys Asn Gln Phe Ser Leu
      65           70           75           80
Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
      85           90           95
Arg Gly Gly Tyr Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val
      100           105           110
Thr Val Ser Ser
      115

```

```

<210> SEQ ID NO 20
<211> LENGTH: 116
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Humanized VH4 for endosialin antibody

```

```

<400> SEQUENCE: 20

```

```

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1           5           10           15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Gly Tyr
      20           25           30
Gly Val Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
      35           40           45

```

-continued

Gly Met Ile Trp Val Asp Gly Ser Thr Asp Tyr Asn Ser Ala Leu Lys
 50 55 60

Ser Arg Val Asn Ile Ser Val Asp Lys Ser Lys Asn Gln Phe Ser Leu
 65 70 75 80

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
 85 90 95

Arg Gly Gly Tyr Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu Val
 100 105 110

Thr Val Ser Ser
 115

<210> SEQ ID NO 21
 <211> LENGTH: 107
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Humanized VL1 for endosialin antibody

<400> SEQUENCE: 21

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly
 1 5 10 15

Asp Arg Val Thr Ile Thr Cys His Ala Ser Gln Asn Ile Asn Val Trp
 20 25 30

Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45

Tyr Lys Ala Ser Asn Leu His Thr Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Gln Ser Tyr Pro Trp
 85 90 95

Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
 100 105

<210> SEQ ID NO 22
 <211> LENGTH: 107
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Humanized VL2 for endosialin antibody

<400> SEQUENCE: 22

Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
 1 5 10 15

Asp Arg Val Thr Ile Thr Cys His Ala Ser Gln Asn Ile Asn Val Trp
 20 25 30

Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45

Tyr Lys Ala Ser Asn Leu His Thr Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80

Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Gln Ser Tyr Pro Trp
 85 90 95

Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
 100 105

-continued

<210> SEQ ID NO 23
 <211> LENGTH: 107
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Humanized VL3 for endosialin antibody

<400> SEQUENCE: 23

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15

Asp Arg Val Thr Ile Thr Cys His Ala Ser Gln Asn Ile Asn Val Trp
 20 25 30

Leu Thr Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45

Tyr Lys Ala Ser Asn Leu His Thr Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80

Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Gly Gln Ser Tyr Pro Trp
 85 90 95

Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
 100 105

<210> SEQ ID NO 24
 <211> LENGTH: 107
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Humanized VL4 for endosialin antibody

<400> SEQUENCE: 24

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15

Asp Arg Val Thr Ile Thr Cys His Ala Ser Gln Asn Ile Asn Val Trp
 20 25 30

Leu Thr Trp Tyr Gln Gln Lys Pro Glu Lys Ala Pro Lys Ser Leu Ile
 35 40 45

Tyr Lys Ala Ser Asn Leu His Thr Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Gln Ser Tyr Pro Trp
 85 90 95

Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
 100 105

1. A method for treating or ameliorating cancer, said method comprising:

- (i) administering to a mammal a radioimmunoconjugate, wherein the mammal has received or is receiving a DNA damage response inhibitor (DDRi);
- (ii) administering to a mammal a DDRi, wherein the mammal has received or is receiving a radioimmunoconjugate; or
- (iii) administering to the mammal a DDRi at the same time as administering the mammal a radioimmunoconjugate.

2. The method of claim 1, said method comprising administering to a mammal a DDRi, wherein the mammal has received or is receiving a radioimmunoconjugate.

3.-4. (canceled)

5. The method of claim 1, wherein the radioimmunoconjugate comprises (i) a targeting moiety that is capable of binding to a tumor-associated antigen, (ii) a linker, and (iii) a metal complex of a chelating moiety.

6.-7. (canceled)

8. The method of claim 5, wherein the targeting moiety is an antibody or an antigen-binding fragment thereof.

9. The method of claim 8, wherein the antibody or antigen-binding fragment thereof is an IGF1-R antibody or an endosialin (TEM-1) antibody, or an antigen-binding fragment thereof.

10.-11. (canceled)


12. The method of claim 5, wherein the metal complex comprises a radionuclide.

13. (canceled)

14. The method of claim 12, wherein the radionuclide is an alpha emitter selected from the group consisting of Astatine-211 (^{211}At), Bismuth-212 (^{212}Bi), Bismuth-213 (^{213}Bi), Actinium-225 (^{225}Ac), Radium-223 (^{223}Ra), Lead-212 (^{212}Pb), Thorium-227 (^{227}Th), and Terbium-149 (^{149}Tb).

15. The method of claim 14, wherein the radionuclide is ^{225}Ac .

16. The method of claim 5, wherein the radioimmunoconjugate comprises the following structure:



wherein B is the targeting moiety.

17. The method of claim 1, wherein the DDRi is a PARP inhibitor.

18. The method of claim 17, wherein the PARP inhibitor is a small molecule PARP inhibitor.

19. The method of claim 18, wherein the small molecule PARP inhibitor is selected from the group consisting of niparib, niraparib, olaparib, talazoparib, pamiparib, rucaparib (camsylate), and veliparib, or an analog thereof.

20. The method of claim 19, wherein the small molecule PARP inhibitor is olaparib or an analog thereof.

21. The method of claim 1, wherein the DDRi is an ATR inhibitor.

22. The method of claim 21, wherein the ATR inhibitor is a small molecule ATR inhibitor.

23. The method of claim 22, wherein the small molecule ATR inhibitor is selected from the group consisting of AZ20, AZD0156, AZD1390, AZD6738, BAY-1895344, EPT-46464, M3541, M4344, M6620 (formerly known as VE-922 or VX-970), NU6027, and VE-821, or an analog thereof.

24. The method of claim 23, wherein the ATR inhibitor is BAY-1895344 or an analog thereof.

25. The method of claim 1, wherein the DDRi is a DNA-protein kinase (DNA-PK) inhibitor, a WEE1 inhibitor, a Chk1 inhibitor, or a Chk2 inhibitor.

26. (canceled)

27. The method of claim 1, wherein the mammal is a human.

28. (canceled)

29. The method of claim 1, wherein the cancer is selected from the group consisting of breast cancer, non-small cell lung cancer, small cell lung cancer, pancreatic cancer, head and neck cancer, prostate cancer, colorectal cancer, sarcoma, adrenocortical carcinoma, neuroendocrine cancer, Ewing's Sarcoma, multiple myeloma, and acute myeloid leukemia.

30.-31. (canceled)

32. The method of claim 1, wherein said administering results in a decrease in tumor volume, a stable tumor volume, or a reduced rate of increase in tumor volume.

33. The method of claim 1, wherein said administering results in a decreased incidence of recurrence or metastasis.